>> SO AS WE CALL YOUR NAME
PLEASE INTRODUCE YOURSELF AND
YOUR INSTITUTION.
[ROLL CALL].
>> I WOULD LIKE TO OPEN WITH A
PRESENTATION SUMMARIZING THE
STATE OF THINGS.
FIRST SADLY SHARING NEWS OF THE
RECENT PASSING OF JUDY.
WE HAVE KNOWN HER.
AND INCLUDING MEMBERSHIP AS A
NACA MEMBER.
IT IS TRAGIC AND A LOSS FOR ALL
OF US.
WE LIKE TO TAKE A MOMENT IF
ANYBODY ELSE WOULD LIKE TO MAKE
SOME COMMENTS?
>> THIS IS CHARLOTTE PETERSON
WHY THE TRAGIC LOSS.
JUDY WAS VERY INSTRUMENTAL IN
ENTERING THE FIELD.
SHE WILL BE SORELY MISSED.
I CANNOT TELL YOU HOW MUCH SHE
INFLUENCED MY CAREER.
>> I WOULD LIKE TO MAKE SOME
COMMENTS ON BEHALF.
SHE WAS A LONG TIME GRANTEE WITH
SIGNIFICANT CONTRIBUTIONS.
SHE PARTICIPATED IN LOTS OF
MEETINGS AND WORKSHOPS OVER THE
YEARS AND IS ON LEADERSHIP ROLES
AND NIH PROGRAMS AS WELL MOST
RECENTLY IN WITH THE GUIDANCE
AND EXPERTISE.
THAT WAS QUITE SIGNIFICANT.
AND BEYOND RESEARCH TALENTS AND
ALSO HOLD ON THAT WAS QUITE
IMPRESSIVE IN HER DEATH IS A
MAJOR LOSS FOR US.
>> JUDY HAS BEEN VERY
INFLUENTIAL WITH THE THINGS WE
HAVE BEEN INTERESTED IN.
AND IS 1 OF THE RARE PEOPLE AND
THE PLEASANTNESS OF MEETING HER
AND HELP PRESENT SHE WAS.
AND THEN TO PICK UP THE PHONE
AND CALL HER TO SAY DOES THIS
MAKE SENSE I HAVE KNOWN HER
REALISTICALLY AT LEAST 15 YEARS
NOW AT THIS POINT IN TIME.
IT IS A LOSS FOR THE FIELD JUST
BASED ON HOW HIM AS SHE WAS WITH
SO MANY DIFFERENT PROJECTS AND
WILLING TO SHARE HER KNOWLEDGE
AS WELL AS EXPERTISE.
IT WILL BE A TREMENDOUS LOSS FOR
US IN THE SPACE FOR SURE.
>> I JUST SAID WHAT A LEGACY.
>> AWARE PERSON AS WELL AS
SCIENTIST AND WE WILL MISS HER.
SO NOW WE WILL MOVE TO THE NEXT
SLIDE.
>> WE DO WILL WHERE WE ARE THIS
CLEAR 2024.
WE BEGAN THE YEAR WITH
APPROPRIATION WE ARE UNDER THE
RESOLUTION KEEPING US IN
BUSINESS THROUGH MARCH 8, 2024.
AT THAT POINT THERE WILL BE
APPROPRIATION OR A FURTHERING
RESOLUTION WE WILL TRACK THIS
VERY CAREFULLY.
IN THE MEANTIME IT MEANS WE HAVE
TO BE VERY CAUTIOUS OF FUNDS
AVAILABLE AND PAY LOANS.
AS REFLECTED HERE IN THE INTERIM
ALLOCATIONS OF WHICH WE ARE
FUNDING UNTIL WE KNOW WHERE
BUDGET FOR THE GENERAL PAY
LINE.
AND PAY LINE HERE FOR THE
PERCENTILE 11 THROUGH 13 AND
HIGHER BAR FOR THE MORE
EXPENSIVE AWARDS WE WILL HAVE
THE PAY LINES A QUITE
SUBSTANTIAL DECREASE ON THE PAY
LINE HERE WITH 12 PERCENT 15 AND
17 PERCENT AND FOR THOSE MORE
EXPENSIVE ALZHEIMER'S WORDS
$500,000,000.10 PERCENT OFF AND
THEN 15 AND 13 THE NEXT SLIDE
ILLUSTRATES THE SAME FOR OVERALL
IMPACT SCORES.
MUCH BELOW WHERE WE HAVE BEEN IN
PRIOR YEARS AND WE ARE HOPEFUL
THAT THESE WILL BE MODIFIED AND
IMPROVED IN THE BUDGET PROCESS
AND THEN WE JUST HAVE TO REMAIN
CAUTIOUS AND WE WILL KEEP IN
TOUCH WITH YOU.
BUT WERE LIKELY TO LEARN MORE
BEFORE THE MARCH 8 DEADLINE.
SO WE JUST WANT TO SUMMARIZE THE
PROGRESS OF THE CLINICAL
TRIALS.
THOSE THAT ARE SUPPORTED AND
NEARLY HALF OF THOSE ARE GIVING
CARE AND OTHERS ARE IN THE
CATEGORIES OF TREATMENT AND
PREVENTION.
SO PHARMACOLOGICAL AND
NONPHARMACOLOGICAL INTERVENTIONS
WE DON'T WANT TO STRESS THE
NUMBERS BUT THE DIVERSITY OF
TARGETS THE BUT
THE EARLIER STAGE PHASE 1 AND
2.
DIVERSITY IS QUITE REMARKABLE
AND THE OTHERS THAT ARE
EMERGING.
WITH THE NONPHARMACOLOGICAL
REFLECTS THE WAY THE BASIC
RESEARCH AS WELL AS THE
TRANSLATION THROUGH THE CLINICAL
TRIALS.
AND THAT IS BUILDING UPON PAST
RESEARCH READY FOR THE
DISSEMINATION.
AND WITH THE HEALTH AND
WELL-BEING WITH THE CARE
PROVIDERS AND CAREGIVERS AS WELL
AS INSTITUTIONAL SETTINGS AND SO
ON.
ALSO WITH DIAGNOSTIC IMAGING AND
OTHER TOOLS AND OTHER
PSYCHIATRIC SYMPTOMS SO IT IS
QUITE A REMARKABLE EXPANSION
WITH THE DIVERSITY TARGETS AS WE
ALL RECOGNIZE A PROCESS WITH
INDIVIDUALS SET OF CONTRIBUTING
CAUSES THAT HAVE BEEN ADDRESSED
BY VERY TARGETED TRIALS.
NEXT FOR THE ONGOING ACTIVITY AT
THE REQUEST OF CONGRESS WITH THE
NATIONAL ACADEMIES AND THEN TO
IDENTIFY PRIORITIES WITH THE
RESEARCH PRIORITIES THROUGH
TRANSLATION LOOKING FOR GAPS AND
RECOMMENDED PRIORITIES AND THE
COMMITTEE WAS ESTABLISHED THE
FOLLOWING LAST YEAR THE MOST
RECENT OF WHICH WAS LAST WEEK.
WE HAD A REPORT IN EARLY 2025.
LOOK AT THE PUBLIC SESSIONS WHEN
AVAILABLE.
THIS IS A WELCOME BIT OF INFO TO
US.
WE ARE GRATEFUL FOR ALL OF THOSE
PARTICIPATING AS WELL AS THOSE
ON THE PANEL.
THE MORE INPUT WE HAVE THE
BETTER INFORMED RESEARCH
PRIORITIES AND THE BETTER FOR
ALL.
WE HAVE A DELIGHTFUL OPPORTUNITY
SOME OF YOU MAY RECALL WITH THE
LEADERSHIP WITH THE SPECIAL
POPULATIONS WE HAVE OUTREACH IN
THE I CHING COMMUNITIES.
WE TOOK SOME ADVANTAGE OF SUCH A
VISIT WITH LEADERSHIP.
AND IT WAS A FANTASTIC
OPPORTUNITY TO SEE A VERY
IMPRESSIVE MEDICAL SCHOOL THAT
HAS NOW BEEN DEVELOPED AS WELL
AS RESEARCH SETTINGS OVER THE
PAST YEAR AND WE APPRECIATE
THEIR WILLINGNESS TO HOST US.
AND THEN AND EXEMPLAR AND IN
ADDITION TO MEETING WITH THE
CHEROKEE NATION.
WE ARE OKLAHOMA STATE COLLEGE OF
MEDICINE AT THE CHEROKEE
NATION.
THE ONLY COLLEGE OF MEDICINE A
NATIVE AMERICAN SOVEREIGN LAND
IN THE COUNTRY.
THE REGIONAL MEETING THE
FOLLOWING DAY HELD AT OKLAHOMA
STATE UNIVERSITY.
BROUGHT TO GATHER PARTNERS FROM
A VARIETY OF INSTITUTIONS MANY
THAT ARE NOT FAMILIAR WITH NIH
RESEARCH IN GENERAL.
AND TO BRING THESE VARIOUS
COMMUNITIES TO ESTABLISH
RELATIONSHIPS WHICH WE HOPE WILL
LEAD TO THEIR ENGAGEMENT AND AND
LEADERSHIP FROM THOSE
INSTITUTIONS DASH AND SERVICE
WELL TO FURTHER THE CAUSE OF
OUTREACH AND INCLUSION WITH
OUTREACH EFFORTS.
>> DEPUTY CHIEF FROM THE
CHEROKEE NATION PARTICIPATING IN
THE DAY 2 SESSION WITH THE
LIAISON BETWEEN THE CHEROKEE
NATION AND THE OUTREACH.
AND THEN PATRICIA JONES GREAT
CREDIT TO HER AND ALL THOSE WHO
ARRANGED THE VISIT AND ALSO
PLANNING FOR FUTURE VISITS AND
WHERE THERE IS LESS
OPPORTUNITY.
AND THIS IS JUST PROGRESS
DISSEMINATING WITH A LIST OF
PRESS RELEASES AND ALL THOSE
THAT HAVE PARTICIPATED.
6 WITH CONGRESSIONAL BRIEFINGS
AND STAFF.
WE JUST WANT TO SHARE WITH YOU
THIS IS THE 50th ANNIVERSARY
WE INVITE YOU TO LEARN MORE
ABOUT THE ACCOMPLISHMENTS TO
CELEBRATE AND WE LOOK FORWARD TO
OUR FUTURE AND THEN THE WAY TO
SHARE IN YOUR CELEBRATION.
HONORING SOME OF THE MANY
SCIENTIST NIH WITH THE
RECOGNITIONS OF THEIR WORK WITH
THE BREAKTHROUGH PRIZE
FOUNDATION FOR HIS WORK OVER THE
GENERATION AND THEN ONCE AGAIN
THIS YEAR GOING OVER THE COURSE
OF THE MEETING WE WILL GO BACK
TO IN PERSON BUT IT IS OPEN FOR
REGISTRATION.
THE COGNITIVE AGING SUMMIT IS
COMING UP.
AS IS THE RESEARCH SUMMIT IN
SEPTEMBER.
WE ARE ANNOUNCING WE HAVE A NEW
NIH DIRECTOR.
SHE'S ALREADY PROVEN TO BE AN
OUTSTANDING LEADER.
THE GUIDING PRINCIPLES TO BE
SUMMARIZED HERE AND BULLETS THE
PRIORITIES FOR HER ARE BRINGING
TOGETHER RESEARCH DATA, BETTER
HARMONIZATION AND COMMUNICATION
ACROSS ALL DATABASES.
AND THOSE BARRIERS TO
PARTICIPATION.
>> THE OTHER INTEREST IS IN THE
ADVANCED RESEARCH AND NIH HAS
BEEN A LEADER IN THIS RESEARCH
AND WE ARE LOOKING FORWARD TO
MONICA'S LEADERSHIP IN THIS
AREA.
WE ARE COMMITTED EVEN WITH THE
FUNDS WE HAVE AND LOOKING FOR
POTENTIAL NEW DISCOVERIES.
AND ALSO RECENTLY AN APPOINTMENT
LAST MONTH WITH THE NEW DIRECTOR
OF NCI.
FROM VANDERBILT UNIVERSITY AND
WE LOOK FORWARD TO INTERACTIONS
BETWEEN NCI AND AN IA.
SIMILARLY WE HAVE A NEW NAME
DIRECTOR OF AN A - - NIAID IN
THE FALL.
WORKING ACROSS HER RESEARCH AND
EDUCATION AT A VERY COLLEGIATE
LEVEL OF DIRECTORS.
AND FINALLY WE ARE HAPPY TO ADD
SOME STAFF UPDATES.
MANY STAFF HAS JOINED US SINCE
WE LAST SPOKE.
THIS IS STARTING WITH BSR.
>> WE ARE HAPPY TO INTRODUCE 5
NEW STAFF MEMBERS THAT HAS
JOINED US RECENTLY.
FIRST OUR CLINICAL TRIALS
COORDINATOR IN THE CLINICAL
TRIALS OFFICE.
JENNIFER IS PROVIDING OVERSIGHT
OF THE CLINICAL TRIALS PORTFOLIO
INCLUDING STEADY PROGRE
PROGRESS, POPULATION DIVERSITY
AND DATA AND SAFETY MONITORING.
CONDUCT AND RISK ASSESSMENT.
SHE IS A PHD IN COGNITIVE
SCIENCE FROM THE UNIVERSITY OF
ROCHESTER IN PRIOR TO JOINING US
ASSISTANT PROFESSOR AT
UNIVERSITY OF NEBRASKA MEDICAL
CENTER LOOKING AT BEHAVIORAL
DATA TALK ABOUT DEMENTIA AND
AGING POPULATIONS.
NEXT OFFICE OF DATA RESOURCES
AND ANALYTICS REBECCA JOINED US
AS A PROGRAM OFFICIAL AS A AAA
AS POLICY FELLOW.
ALSO LOOKING ON AI
COLLABORATIONS, DATA SHARING AND
PUBLIC/PRIVATE PARTNERSHIPS
INCLUDING HOW RESEARCHERS CAN
USE SOCIAL MEDIA AND
PARTNERSHIPS TO RECRUIT
PARTICIPANTS INTO RESEARCH.
SHE IS A LEAD IN THE INTERNAL
PROCESS TO SHARE WITH THE NIH
POLICIES.
PRIOR TO JOINING WITH THE
POSTDOC TRAINING UNIVERSITY OF
CAROLINA CHAPEL HILL AFTER
EARNING PHD FROM THE UNIVERSITY
OF MARYLAND.
NEXT SLIDE.
NEXT WE HAVE INDIVIDUAL
PROCESSES BRANCH PROGRAM
OFFICIAL MELISSA IS MANAGING BSR
PORTFOLIO ON BEHAVIORAL
INTERVENTION RESEARCH WHAT THE
FOCUS ON CAREGIVING AND THOSE
WHO CARE FOR THEM.
JOINING US FROM AN IDC ARE.
SHE COLLABORATES WITH HER OWN
STAFF HERE AS WELL AS MULTIPLE
INITIATIVES TO TAKE THIS
APPROACH TO BEHAVIORAL
INTERVENTION AND PRIOR TO THAT
WORKING WITH DRUG ABUSE WITH
CLINICAL PSYCHOLOGY FROM
UNIVERSITY OF ARIZONA COMPLETING
POSTDOC WORK AT UNIVERSITY OF
PENNSYLVANIA.
NEXT JOINING THIS MONTH OFFICE
OF THE DIRECTOR TO OVERSEE THE
TRAINING AND CAREER DEVELOPMENT
PORTFOLIO ALSO CONTACT FOR SMALL
BUSINESS ACTIVITIES WE ARE VERY
HONORED TO BE RECRUITING HIM
AFTER SEVERAL YEARS OF DIRECTING
OUR TRAINING.
HE WAS A SCIENTIFIC OFFICER
PRIOR TO THIS AND THEN PRIOR TO
THAT A RESEARCH FELLOW SO HE HAS
A RICH BACKGROUND.
HIS TRAINING IS MOLECULAR
PHYSIOLOGY WITH HIS DEGREE FROM
HANOVER IN GERMANY AND POSTDOC
TRAINING IN PITTSBURGH.
HE HAS A LONG-STANDING INTEREST
IN SOCIAL SCIENCES RESEARCH WE
ARE DELIGHTED TO GET HIM AND HIS
EXPERTISE.
AND JOINING OFFICE OF THE
DIRECTOR FOR ES A WORKING WITH
MEMBERS OF THE ADMIN TEAM AND IS
HANDLING A VARIETY OF NEEDS.
HE HAS A BACHELORS DEGREE IN
HISTORY FROM UCLA COMES TO US
WITH RICH EXPERIENCE INCLUDING
SUPERVISORY ROLES SO JOIN ME TO
WELCOME THE NEW BSR STAFF
MEMBERS AND NOW I WILL TURN IT
OVER.
>> THE DIVISION OF AGING BIOLOGY
WE HAVE 1 STAFF MEMBER WE WOULD
LIKE TO WELCOME.
KATHERINE KIM RECENTLY JOINED AS
AND FTE AS SCIENTIFIC PROGRAM
ANALYST SHE WAS A MASTER STUDENT
AND UNIVERSITY OF MARYLAND.
HER ROLE IS SHE MANAGES THE HBP
PROGRAM AND SUPPORTS THE
COORDINATION OF OTHER ACTIVITIES
INCLUDING THE PROBLEMATIC
ASPECTS AND HELPS US WITH THE
GRANT CODING ASSIGNMENTS AND
PROVIDES HELP WITH CLINICAL
TRIAL OVERSIGHT AND SHE ALSO
WORKS ON PORTFOLIO ANALYSIS
GRANTS.
WE WOULD LIKE TO WELCOME
KATHERINE.
>> HELLO.
WE ARE PLEASED TO WELCOME SARAH
CRAIG JOINING US AS A PROGRAM
OFFICIAL AT THE CLINICAL
GERONTOLOGY BRANCH.
SHE WORKS WITH US AND DOING WORK
THAT IS BEEN VERY USEFUL WITH
THIS DUTIES OF LONGEVITY.
[INAUDIBLE]
SO WE ARE VERY GLAD SHE IS HERE.
>> I AM HAPPY TO INTRODUCE
SEVERAL NEW STAFF TO THE
DIVISION OF EXTRAMURAL
ACTIVITIES.
WE ARE VERY FORTUNATE TO HAVE
HIRED 5 NEW OUTSTANDING GRANTS
MANAGEMENT SPECIALISTS INCLUDING
TO THE CONTACTS MANAGEMENT
BRANCH.
MS. BEAN JOINS US FROM US
FERTILITY.
AUSTIN JOINS US FROM THE
ADMINISTRATIVE SUPPORT
SPECIALIST POSITION FROM
DEPARTMENT OF ENERGY.
MORGAN JOINS US AS A FORMER
PROGRAM COORDINATOR FROM
FREDERICK NATIONAL LAB.
AND NEXT JOINING US FROM
EXECUTIVE CUSTOMER RELATIONS
POSITION WITH AMAZON AS A
FINANCIAL MANAGEMENT
ANALYST, MS. MCLEOD AND THEN WE
HAVE ANNA JOINING US AS A FORMER
TEACHER.
WE ARE VERY FORTUNATE TO GET
THESE 5 NEW MEMBERS INTO THE
GRANTS MANAGEMENT PROGRAM.
NEXT WE HAVE OFFICE OF CLINICAL
RESEARCH WE HAVE RECENTLY HIRED
MICHELLE SNYDER.
WE WELCOME HER AS A REGULATORY
POLICY SPECIALIST WORKING ON
POLICIES AND PROCEDURES IN THE
CLINICAL SUPPORT CONTRACT SHE IS
A CERTIFIED PROJECT MANAGER AND
A GENETIC COUNSELOR WITH 16
YEARS OF GENETICS AND MANAGEMENT
HEALTH COMMUNICATIONS WEBSITE
CONTENT STRATEGY AND BUSINESS
PROCESS IMPROVEMENT.
SHE RECEIVED HER MASTERS IN
GENETIC COUNSELING AND HAS A BS
IN BIOLOGY FROM CORNELL.
SHE PREVIOUSLY SERVED WITHIN THE
DEA OFFICE AND WAS INSTRUMENTAL
TO DEVELOP POLICIES AND
PROCEDURES AND PUBLISHING OUR
INTERNAL LAB MATERIAL.
NEXT WE HAVE HIRES WITHIN THE
OFFICE OF STRATEGIC EXTRAMURAL
PROGRAMS.
FIRST YOU PROBABLY KNOW TODD BUT
NOW HAS A NEW ROLE AS SENIOR
ADVISOR ON BIOMEDICAL INNOVA
INNOVATION.
HE WILL DEVELOP STRATEGIES FOR
TARGETED BIOMEDICAL PRODUCT
ASSESSMENT INVESTMENTS ALIGNED
WITH THE NIA MISSION AND ALSO
HAS A ROLE OF THE OFFICE OF
STRATEGIC EXTRAMURAL PROGRAM
DIRECTOR AND THEN TO BE FOCUS ON
TRAINING AND DEVELOPMENT AND
SMALL BUSINESS RESEARCH
PROGRAMS.
TODD HAS A PHD FROM EINSTEIN
COLLEGE OF SCHOOL OF MEDICINE
WITH A CERTIFICATE OF TECHNOLOGY
FROM JOHNS HOPKINS BUSINESS
SCHOOL.
HE ALSO COMPLETED A POSTDOC
FELLOWSHIP AT PFIZER.
LEADING THE RESEARCH EFFORTS IN
COLLABORATION WITH WASHINGTON
SCHOOL UNIVERSITY OF MEDICINE.
RECEIVING SEVERAL PRESTIGIOUS
AWARDS AND HONORS INCLUDING THE
NCI LEADERSHIP DEVELOPMENT AWARD
SEVERAL DIRECTORS OF WORDS AND
ALSO VOLUNTEERS.
WE ARE FORTUNATE TO CONTINUE TO
HAVE TODD IN HIS CAPACITY AS A
SENIOR ADVISOR ON BIOMEDICAL
INNOVATION.
AND THEN WE HAVE DOCTOR LAURA
MAJOR 1 OF OUR NEW TRAINING
OFFICERS SHE WILL ASSIST CAREER
DEVELOPMENT APPLICANTS AND
DEVELOP TRAINING AND FUNDING
OPPORTUNITIES AND INITIATIVES
AND COMMUNICATION MATERIALS.
CHOSE TO CONDUCT ANALYSIS WITH
OPPORTUNITIES WITH NIH FUNDING
WITHIN THE PROGRAM.
PRIOR TO JOINING OS EPA PROGRAM
OFFICER WITH BEHAVIORAL AND
SOCIAL RESEARCH AND MANAGED TO
GRANT PORTFOLIO FOCUSED ON
INSTITUTIONAL TRAINING.
SHE HAS HER DOCTORATE IN
PHILOSOPHY AND HEALTH BEHAVIOR
FROM GEORGE WASHINGTON
UNIVERSITY.
>> GOOD MORNING I AM PLEASED TO
ANNOUNCE THE NEW STAFF OF THE
OFFICE OF ADMINISTRATIVE
MANAGEMENT.
FIRST I WILL START WITH THE
FINANCIAL MANAGEMENT BRANCH.
WE ARE PLEASED TO INTRODUCE
CINDY HENDRICKSON A NEW
SUPERVISORY BUDGET ANALYST.
HER EXPERTISE IS IN LEADING
BUDGET FORMULATION AND
EXECUTION.
SHE COMES FROM THE NIH CENTER
FOR INFORMATION TECHNOLOGY IS A
BUDGET ANALYST.
OUR WORKFORCE AND ADMINISTRATIVE
MANAGEMENT BRANCH HAS HIRED A
FEW STAFF.
FIRST HANNAH COOPER A NEW
PROGRAM SPECIALIST WORKING ON
OPTIMIZING THE WORKFORCE AND
ADMINISTRATIVE BRANCH
PERFORMANCE.
HER BACKGROUND IS HR SPECIALIST
WITH THE USAF AND ANOTHER NEW
SENIOR ADVISOR IS MARLENE GUZMAN
OFFICE OF STRATEGIC WORKFORCE
PLANNING.
SHE PREVIOUSLY SERVED AS ADVISOR
AND CONTRACTOR IN OAM AND
RECENTLY CONVERTED TO FTE
FEDERAL EMPLOYEE.
AND LASTLY RECENT HIGHER CAMERA
AND MORE A NEW PATHWAYS STUDENT
INTERN.
HE HAS HR EXPERTISE AND WILL
WORK CLOSELY WITH HR LIAISON
TEAM AND JOINS US FROM HR
ASSAY.
>> GOOD MORNING I AM PLEASED TO
ANNOUNCE 2 NEW STAFF HIRES IN
THE OFFICE OF THE ASSOCIATE
DIRECTOR IT'S A NEW OFFICE IN
THE LAST YEAR INTRODUCING
OVERSEAS LEGISLATION POLICY AS
WELL AS STRATEGIC PLANNING.
I AM PLEASED TO ANNOUNCE SHALL
BE -- -- MS. SMITH COORDINATE
AND ASSIST PROJECTS AND COMING
TO US FROM THE COMMUNICATIONS
BUT PREVIOUSLY WORKING WITH
STRATEGIC INDICATIONS AND PUBLIC
RELATIONS AND WILL BE DOING VERY
SIMILAR WORK FOR US AS WELL AND
ALSO THE PROGRAM
SPECIALIST, DAVID COMES US TO
THE DEPARTMENT OF AGING AND
DISABILITIES AND ORGANIZING THE
TOWN HALL MEETINGS AND
ENGAGEMENT AND PROJECTS UNDER MY
DIRECTION AS WELL AS SHELBY.
BEFORE I TURN IT OVER I WENT TO
INTRODUCE COURTNEY AS A NEW
DIRECTOR OF OFFICE OF
LEGISLATION AND POLICY.
SHE WAS RECENTLY PROMOTED TO
THIS POSITION FROM DEPUTY
DIRECTOR.
SHE HAS BEEN WITH NIH SINCE 2016
STARTING AS A PRESIDENT
MANAGEMENT FELLOW AND ALSO HAS
WORKED AS THE OUTREACH LEAD FOR
SOME TIME.
WE ARE PLEASED TO HAVE HER ON
BOARD AS THE NEW OPM DIRECTOR.
>> THANK YOU.
I'M HAPPY TO WELCOME MEGAN
MILLER A NEUROBIOLOGIST BY
TRAINING WORKING AT THE
INTERSECTION OF SCIENCE AND
POLICY FOR SEVERAL YEARS.
SHE HAS EXPERIENCE IN PUBLIC AND
NONPROFIT SETTINGS.
BS IN BIOLOGY AND MICROBIOLOGY.
PHD IN BIOMEDICAL SCIENCES FROM
THE UNIVERSITY OF CONNECTICUT
AND A GRADUATE CERTIFICATE OF
PUBLIC LEADERSHIP AND MANAGEMENT
FROM YUKON SCHOOL OF PUBLIC
POLICY.
SHE COMPLETED NIH POSTDOCTORAL
FELLOWSHIP AT YALE SCHOOL OF
MEDICINE AND TRIPLE A POLICY
FELLOWSHIP.
SHE WILL BE CO- LEADING EFFORTS
AROUND THE INTERNATIONAL
ACTIVITIES AS WELL AS SUPPORTING
CONGRESSIONAL AND OTHER EXTERNAL
ENGAGEMENTS.
WE ARE HAPPY TO WELCOME HER.
>> GOOD MORNING.
I AM DIRECTOR OF THE OFFICE OF
COMMUNICATIONS AND PUBLIC
LIAISON AT NIA.
I AM PLEASED TO ANNOUNCE OUR
STUDENT TRAINEE WITH
ADMINISTRATIVE SUPPORT WORKING
ON SEVERAL PROJECTS INCLUDING
SOME PUBLIC ANALYSIS AND HEALTH
ATTIC - - EQUITY AND HEALTH
LITERACY AUDIT AND ACCESSIBILITY
IMPROVEMENTS.
JOINING US FROM THE NATIONAL
HEART AND BLOOD INSTITUTE.
WELCOME.
>> I AM PLEASED TO TELL YOU
ABOUT THE NEW HIRES IN HER
FAMILY.
FROM THE ADMINISTRATIVE OFFICER
WITH PROCUREMENT AND OUTREACH
AND TRAINING AND JOINS US FROM
THE DEPARTMENT OF VETERAN
AFFAIRS.
NEXT HOUR PROGRAM SPECIALIST
ASSIST WITH RECRUITMENT AND
STRATEGIC PLANNING AND WITH THE
EXPANSION AND JOINS US FROM V.A.
MARYLAND HEALTHCARE SYSTEM.
AND UP NEXT OUR PROGRAM
SPECIALIST COORDINATING IRP
PERFORMANCE OF WORDS AND MANY
OTHER MEN JOINING US FROM THE
NIH OFFICE.
WITH A PROFIT MANAGEMENT
SPECIALIST.
AND THEN WE HAVE THE MEMBER AT
NETWORKING COMMUNITY
TECHNOLOGIES SECTION.
AS AN IT SPECIALIST SHE WILL
OVERSEE AND COORDINATE SUPPORT
ACTIVITIES, ESPECIALLY
ESCALATING EMERGENCIES TO THE
HELP DESK AND MANAGES THE
APPLICATIONS FOR THE MAC SYST
SYSTEMS.
PREVIOUSLY AND A CONTRACTING
POSITION FOR NIA.
NEXT, RICK WORDS IS THE IT
SPECIALIST SUPPORTING THE DATA
CENTER AND INFRASTRUCTURE
EFFORTS.
JOINING US FROM THE USAF LEGAL
INFORMATION SERVICES.
WE HAVE A BIOLOGIST GENE
REGULATION SECTION.
SHE CONDUCTS RESEARCH AROUND THE
MOLECULAR MECHANISMS AND
PROCESSES THAT CONTRIBUTE TO AGE
ASSOCIATED CHANGES IN PHYSIOLOGY
INCLUDING DISEASES HIS
PREVALENCE INCREASE WITH AGE AND
HAS BEEN A CONTRACTOR WITH NIA
SINCE 2015.
NEXT GORDON THOMPSON PROGRAM
SUPPORT ASSISTANT COORDINATES
EFFORT FOR TRAVEL PURCHASING A
NEW HIRE AND WAS A CONTRACTOR
POSITION WITH NIA.
AND NEXT WE HAVE A BIOLOGIST WHO
LEVERAGES EXPERTISE IN LONG WE
SEQUENCING AND JOINING US FROM
LAB TECH CONTRACTING POSITION
FOR NIH.
UP NEXT TENURE-TRACK
INVESTIGATOR FROM THE MOLECULAR
AND PATHOLOGY UNIT.
SHE USES MULTI- ONYX TECHNIQUES
TO UNRAVEL THE UNDERLYING
DISEASES AND DEMENTIA.
COMING FROM UC SAN FRANCISCO.
>> THANK YOU FOR THAT IMPRESSIVE
PRESENTATION AND ALL THE
WONDERFUL NEW TALENT.
JUST AS A REMINDER TO ALL OF YOU
KEEP INFORMED WHAT'S GOING ON
THROUGH THE VARIOUS LINKS.
THANK YOU AND NOW WE WILL OPEN
FOR DISCUSSION FOR ANYTHING YOU
HAVEN'T HEARD OVER THE PAST 40
MINUTES.
CONVERSATIONS OR QUESTIONS?
>> I HAVE A COMMENT.
I WANT TO DO THINK THE ENTIRE
TEAM FOR MAKING THE TRIP TO
INDIAN COUNTRY AT CHEROKEE
NATION.
WANT TO TELL EVERYBODY THAT THE
TEAM WAS THE FIRST 1 EVER TO
COME TO CHEROKEE NATION AND HAD
A FIRSTHAND OPPORTUNITY.
THEY WERE EXTREMELY THRILLED AND
I WISH MORE NIH LEADERS TAKE THE
TIME TO COME AND SEE FOR
THEMSELVES WHAT THE CHEROKEE
INDIAN PEOPLE ARE DOING WITH
VERY VERY LIMITED RESOURCES.
I WANT TO THANK EVERYBODY FOR
MAKING IT HAPPEN.
>> THANK YOU FOR HELPING TO
FACILITATE THAT.
IT WAS AN EXTRAORDINARY
EXPERIENCE.
ANYONE WHO HAS AN OPPORTUNITY
SHOULD TAKE ADVANTAGE OF IT.
AND I HAVE SHARED WITH MY
COLLEAGUE LEADERSHIP.
WE WILL SEE WHAT COMES FROM
THIS.
ALSO DOING IF YOU HAVE THOUGHTS
ABOUT GEOGRAPHIC
AREAS, LOCATIONS WHERE THERE HAS
BEEN UNDER OPPORTUNITY TO
INTERACT CLICKS IF YOU HAVE
SUGGESTIONS.
OFTEN AS A HOSTING INSTITUTION
HAVE A RESEARCH PRESENCE BUT
ALSO AS AN ORGANIZER FOR
MULTIPLE INSTITUTIONS SO WE ARE
OPEN TO SUGGESTIONS.
>> GUY WORD MENTION THE HARD
WORK BY A DOCTOR JONES AND HER
TEAM TO MAKE THIS HAPPEN.
>> 2 THINGS COMING ACROSS FROM
THE PRESENTATION AT A HIGH LEVEL
HOW MANY DIFFERENT CREATIVE
APPROACHES AND IA HAS PUT
TOGETHER?
I THINK THAT IS IMPRESSIVE AND
THE OPPORTUNITIES FOR FEEDBACK
IT JUST SEEMS TO HAVE A WIDE
RANGE OF IDEAS AND THAT'S ALSO
APPRECIATED WE APPRECIATE THOSE
2 PRINCIPLES.
>> BEFORE I COMMENT I SAW
SOMEONE HAD THEIR HAND UP ASKING
FOR SUGGESTIONS WHERE NIH COULD
VISIT I HAVE LESS OF A
SUGGESTION OF A PLACE THAT MORE
OF A SUGGESTION OF AROUND THE
VISITS.
WE HEARD YESTERDAY FROM THE
COMMUNITY COLLEGES TO RECRUIT
THE NEXT GENERATION OF AGING
RESEARCHERS AND I CAN IMAGINE
BUT A POWERFUL THING IT WOULD BE
TO HAVE A CONTINGENT THAT WE SAW
ON THE PICTURE TAKING PART IN AN
AGING AND RESEARCH DAY AT A
BUNCH OF COMMUNITY COLLEGES IN
AN AREA MAYBE THAT COULD BE
TIMED WITH OTHER LEADERS GOING
ON THAT COULD BE IN TOWN
PHILADELPHIA IN JULY IS AN
EXAMPLE.
BUT THAT IS POTENTIALLY A VERY
INSPIRING AND POWERFUL TYPE OF
VISIT.
>> AND IT IS CONSISTENT WITH
WHAT WE'VE TRIED TO DO IN THE
PAST.
WE APPRECIATE THE COMMENT WE MAY
HAVE A HOST INSTITUTION OR
UNIVERSITY BUT THEN COMMUNICATE
WITH THE COMMUNITY COLLEGES ARE
OTHER INSTITUTIONS THAT ARE NOT
TRADITIONAL RESEARCH
INSTITUTIONS AND PEOPLE TRAVEL
HUNDREDS OF MILES SOMETIMES TO
THESE REGIONAL MEETINGS AND WE
WILL CONTINUE TO DO THAT.
>> I WAS JUST THINKING OF THE
PRESENTATIONS.
I WAS SMILING THE WHOLE TIME IT
IS TRULY EXCITING MY HEART WAS
JUMPING TALK ABOUT THE VISIT
WITH THE CHEROKEE NATION I LOVE
THIS KIND OF WORK.
IT IS RIGHT THERE WITH THE
PEOPLE.
IT IS EXTREMELY POWERFUL.
AND ALSO 1 SUGGESTION.
I'M PERSONALLY LEARNING MORE OF
US TERRITORIES.
BUT JUST IN GENERAL AND THE
COMMUNITIES THAT TYPICALLY THAT
WE DON'T TALK TOO MUCH ABOUT
THEM AND THEN TO ESTABLISH THE
CONVERSATIONS.
>> YES PUERTO RICO IS ALSO 1 OF
OUR SUCCESSFUL PLACES.
>> I WAS GOING TO ECHO THE SAME
THING GRACIOUSLY HOSTING US IN
2021 DOING A FABULOUS JOB TO
SPREAD THE WORD GARNERING
SUPPORT FROM 15 OTHER ACADEMIC
INSTITUTIONS AND RESEARCH
LABORATORIES ON THE ISLAND A
WONDERFUL TURNOUT IT HAPPENED
VIRTUALLY IT WAS THE FIRST
OPPORTUNITY TO OFFER A HYBRID
FORMAT BUT THE ENTHUSIASM WAS NO
DIFFERENT BUT WE WILL CERTAINLY
ADD THAT TO THE LIST TO EXPLORE
OTHER US TERRITORIES.
>> SO JUST THINKING ABOUT WHY
THE PROGRAMS ENGAGE PRECOLLEGE
BUT ALSO COLLEGE STUDENTS TO
ACTIVELY PURSUE CAREERS AND I
THINK IF WE COULD ADD AGING TO
THE CONVERSATION IT WOULD BE SO
HELPFUL.
IN JUST THE LARGEST COLLEGE
SYSTEM IN THE WORLD IS CAL
STATE.
MY SISTER IS A DEAN THERE.
SHE RUNS THE STEM PROGRAM.
IF THAT COULD BE OF INTEREST I
WOULD BE HAPPY TO HELP MAKE
CONNECTIONS THEY ARE JUST AS A
CONSIDERATION WITH UNTAPPED
TERRITORY FOR NIH AND ALL OF THE
POTENTIAL.
>> COMMENTS OR QUESTIONS?
>> THANK YOU ALL FOR BRINGING
ENGAGED DISCUSSION.
>> THANK YOU.
NEXT TO GIVE YOU AN UPDATE ON
FUTURE MEETINGS 2024 AND 2025.
THE NEXT 2 IN PERSON MEETINGS
MAY 21 AND 22 AND SEPTEMBER 18
AND 19.
AND IN 2025 MAY 13 AND 14 AND
SEPTEMBER 17 AND 18.
STAY TUNED FOR THOSE AND WE WILL
BE SENDING OUT MORE INFORMATION
IN THE FUTURE.
SOMETHING ON THE AGENDA IS THE
CONSIDERATION OF NATIONAL
ADVISORY COUNCIL ON AGING THE
MEETINGS ON THE LAST COUNSEL WAS
SEPTEMBER 2023 AND THEN PROVIDED
WITH A COPY OF THOSE MINUTES ARE
THERE ANY QUESTIONS OR ADDITIONS
TO THE MINUTES?
NOT HEARING ANY TO GET A MOTION
TO APPROVE THE MINUTES?
ALL THOSE IN FAVOR?
ANY OPPOSED?
THANK YOU VERY MUCH WE HAVE
APPROVAL OF THE MINUTES FROM
SEPTEMBER 2023.
>> JUST TO REMIND EVERYBODY IF
YOU ARE NOT SPEAKING PLEASE MUTE
YOUR MICROPHONE.
'S NOW I WILL TURN THIS OVER TO
REPORT ON THE TASK FORCE.
>> THANK YOU SO MUCH.
WE HAD THE TASK FORCE MINORITY
HEALTH DISPARITIES RESEARCH HAS
THE PLEASURE OF PHENOMENAL
PRESENTATIONS YESTERDAY MORNING
GOING TO THE WORKFORCE
PIPELINE.
SO IN THAT SPIRIT WE HAVE DOCTOR
EVANS FROM THE NATIONAL
INSTITUTE OF AGING.
AND SHE TALKED ABOUT THE
RESEARCH PROGRAMS AND THE
EFFORTS UNDERTAKING TO DIVERSIFY
THE TRAINING FOR THE NEXT
GENERATION.
SHE HIGHLIGHTED NIH PROGRAMS
SPECIFICALLY AT NIH WITH THE
NEXT GENERATION OF RESEARCHERS
SHE REMINDED US THAT THE
TRAINING POPULATION AS OF
NOW, JANUARY 2024 IS 197 WHICH I
THINK IS A PHENOMENAL NUMBER.
AND SHE ALSO REMINDED US TO MEET
THE GOALS USING THE STRATEGIES
TO PROMOTE PARTICIPATION IN ALL
NIH SPONSORED TRAINING PROGRAMS
AND THEN TO DEVELOP SPECIFIC
SPECIFICALLY.
SHE HIGHLIGHTED THE SUMMER
PROGRAMS WHICH IS FOR HIGH
SCHOOL STUDENTS AND ALSO
HIGHLIGHTED FOR COMMUNITY
COLLEGES AND WORK FORCE
RECRUITMENT THAT CONNECTING
FEDERAL AND PRIVATE SECTOR
NATIONWIDE WITH HIGHLY MOTIVATED
STUDENTS AND RECENT GRADUATES
WITH DISABILITIES.
ALSO TALKING ABOUT DIVERSITY
AGING RESEARCH AND THEN FOR
INTRODUCTION FOR LABORATORY
SKILLS AND FOR THE BALL TO ROLL
HER HIGH SCHOOL PROGRAM FOR KIDS
YOUNGER THAN 17 YEARS OLD.
WITH THE BIOMEDICAL FOR AGING
SCIENCE.
AND A WORD IS TOUCHED BY THE
RICH CONVERSATION AMONG THE
PANEL MEMBERS AND SOME OF THOSE
THAT I TOOK AWAY WAS EXPLORING
WAYS TO INCLUDE MORE AMERICANS
IN THESE PROGRAMS AND TO LOOK
FOR WAYS FOR THIS NATIONWIDE AND
ARE IMPORTANT FOR THESE TOPICS
TO CONTINUE AND THEN THE PANEL
MEMBERS AND THEN TO IN FACT
IMPACT THE WORKFORCE PIPELINE.
AND THEN WE HEARD FROM DOCTOR
CAMPBELL AND THEN TO MINOR TIES
WOMEN AND DIVERSE UNDERGRADUATES
TO BE LEADERS.
AND THEN WITH THAT MINORITY
SERVING INSTITUTION TO EDUCATE
WOMEN.
OF COURSE THAT WAS MUSIC TO MY
EARS AND THEN TO UNDERSTAND THE
VALUE OF THAT.
HIGHLIGHTING THE CARE PROGRAM
ADVANCING DIVERSITY WITH AGING
RESEARCH PROGRAM AND SHE
HIGHLIGHTED SOME OF THE FEATURES
OF THE CARE PROGRAM IT IS A
MULTI- CARE RESEARCH PROGRAM
FOCUS ON GENERAL SCIENCE AND THE
ONLY PROGRAM IN THE UPPER
MIDWEST AND 100 PERCENT OF THE
STUDENTS A COMPLETE THE PROGRAM
WITH A CAREER IN RESEARCH.
SHE TALKED TO US TALKING ABOUT
THE INJUSTICE THAT WE SEE IN
HEALTH DISPARITIES THAT
ACCUMULATE OVER THE LIFE SPY --
-- LIFESPAN OF A MINOR TIES
POPULATION.
AND FOR ME SOME OF THE KEY
POINTS THAT WE TAKE AWAY FROM
THIS TO HIGHLIGHT HIS TRAINING
THAT NEXT GENERATION OF AGING
RESEARCHERS IS FUNDAMENTAL TO
ADDRESS THE HEALTH OF THE NATION
AND TO DEAL WITH HEALTH
INEQUITIES.
AND ALSO THOSE PERSPECTIVES ARE
ALSO INVALUABLE.
THE IDEA AS A WAY TO SUMMARIZE
SOCIAL JUSTICE WITH AN AGING
POPULATION SO THAT IN TERMS OF
OPPORTUNITIES AGAINST ALL
DEMOGRAPHIC GROUPS IS
FUNDAMENTAL.
AND BEFORE I TURN IT OVER TO
DOCTOR SNYDER FOR HER COMMENTS I
BRIEFLY WANT TO RECOGNIZE DOCTOR
JONES FOR ORGANIZING AND LEADING
US TO THIS POINT.
>> THANK YOU SO MUCH I
APPRECIATE THAT ALSO EXTENDING
MY THINKS BOTH TO YOU AND DOCTOR
JONES FOR INVITING ME.
IT HAS BEEN VERY EXCITING AND
FULFILLING.
THE 2 SPEAKERS.
I WILL GIVE YOU A BRIEF HISTORY
BUT THE 2 SPEAKERS THAT SPOKE.
[INAUDIBLE]
I THOUGHT I WOULD JUST TELL
EVERYBODY AND I LOOKED THIS UP
SO IT WAS FASCINATING FOR ME
ACTUALLY AS AN AMERICAN SURGEON
AND MEDICAL RESEARCHER BORN 19
OH 4 AND HAD AN UNTIMELY DEATH
IN 1950 RESEARCHING BLOOD
TRANSFUSIONS AND WITH APPROVED
TECHNIQUES TO DISTORT - - TO
STORE BLOOD.
AND THIS SAVED THOUSANDS OF
ALLIED FORCES LIVES DURING THE
WAR.
WAS THE MOST PROMINENT
AFRICAN-AMERICAN IN THE FIELD.
BUT HE PROTESTED RACIAL
SEGREGATION AND DONATION OF
BLOOD AND HE RESIGNED HIS
POSITION TO THE AMERICAN RED
CROSS THROUGH 1950.
A REMARKABLE MAN.
L WHOLE WIKIPEDIA PAGE.
I ENCOURAGE YOU TO LOOK AT
THIS.
SO I WILL MOVE ON TO THE
PRESENTATION SO NOW THE FOUNDING
OF THE PROGRAM FROM THE
UNIVERSITY MEDICAID IS -- --
MEDICINE AND SCIENCE IN L.A. IT
IS ONLY THE FOURTH HBCU PROGRAM
OF UNDERREPRESENTED IT COMMUNITY
SCHOOLS FOR TO OBTAIN THE MD.
PARTNERSHIP WITH UCLA THAT SHE
TOLD US ABOUT AND THE HISTORY
AND RESEARCH AND SERVICE.
SHE TOLD US ABOUT THE SOCIAL
ECONOMIC STATUS AND THE PELL
GRANT RECIPIENTS THE FIRST
COHORT WILL GRADUATE 2027 SO SHE
DOESN'T HAVE A LOT OF
INFORMATION YET BUT THEY ARE
VERY EXCITED ABOUT THE PROGRAM
WITH A LONG-STANDING GOAL TO
TRAIN THE NEXT GENERATION OF
DOCTORS.
BUT IN ADDITION TO STRESS THE
UNDERLYING GOALS NOT ONLY WAS
TRAINED DOCTORS AND COMMUNITY
EDUCATION AND OUR SECOND SPEAKER
IS ENGAGING STUDENTS FROM LOCAL
COMMUNITY COLLEGES OF AGING
RESEARCH AND IS THE DIRECTOR OF
THE PIPELINE PROGRAM AT CHARLES
DREW SHE TOLD US MOSTLY HOW MANY
PEOPLE START IN COMMUNITY
COLLEGES AND THEIR GOAL IS TO
PRESENT RESEARCH SO THEY CAN
MOVE ON AND DO RESEARCH AT
UNIVERSITIES THOSE WHO DO END UP
MATRICULATING COME UP FROM A
COMMUNITY COLLEGE STANDPOINT AND
IT'S VERY COMMON FOR PEOPLE TO
START THEIR.
SO TRYING TO BUILD A PIPELINE OF
AGING RESEARCH THROUGH THE
STUDENTS.
THIS IS THE BEGINNING THE GOAL
IS TO HAVE RACIAL ETHNIC DIVERSE
WORKFORCE.
AND THEN WITH AN EXCITING
PRESENTATION ABOUT WHAT THEY ARE
DOING IT IS A GREAT OPPORTUNITY
TO BUILD PIPELINES AND SO THERE
IS A LOT OF DISCUSSION AND THEY
WERE EXCITED TO HEAR OUR
EXCITEMENT ABOUT THE PROGRAMS.
ANOTHER THING THAT WAS DISCUSSED
AS THE DIVERSITY SUPPLEMENTS
THERE'S A REALLY GOOD AVENUE FOR
TRAINING.
AND WE MOVED INTO A DISCUSSION
ABOUT HOW DO WE ENCOURAGE
INSTITUTIONS TO ACTUALLY HAVE
THE INCENTIVE?
AND IT'S ALWAYS HARD TO PEOPLE
TO COME IN A MENTOR THERE'S A
LOT OF DISCUSSION ABOUT THAT.
INTERESTING COMMENTS OF ALL THE
THINGS AVAILABLE AT AN IA TO
LOOK AT.
ALSO MENTIONING THE PROGRAM
WHICH IS A PRE- K PROGRAM SO
OVERALL I THOUGHT IT WAS A GOOD
GROUP OF PEOPLE DISCUSSING HOW
IMPORTANT THE PIPELINE IS TO
CREATE A WORKFORCE OF PEACE IN
THE CAN SEE.
IT WAS A PLEASURE TO DO THIS.
THANK YOU FOR INVITING ME.
>> THANK YOU FOR YOUR SUMMARY.
ANY QUESTIONS OR COMMENTS?
>> I ECHO THE COMMENTS WITH THE
WARM WELCOME BOTH YOU HAVE BEEN
WONDERFUL ADDITIONS TO THE
PROCESS AND WE LOOK FORWARD TO
HEARING WHAT ADDITIONAL IDEAS
THE COUNCIL WISHES US TO PURSUE
AS A TASK FORCE.
STATES THAT WE LOOK FORWARD TO
BEING COCHAIR OF THIS TASK FORCE
AND THE RECOMMENDATIONS IN
FUTURE MEETINGS.
>> I JUST WANT TO SAY I THOUGHT
THIS WAS AND INSPIRING
PRESENTATION FOR WHAT PEOPLE
WERE DOING ON THE GROUND WITH
THE ATTENTION THAT DOCTOR JONES
BRINGS TO THE TASK FORCE CHAIRS
WITH THAT SORT THE
PRESENTATIONS.
AND REALLY TO BE INSPIRED.
>> ANY OTHER QUESTIONS OR
COMMENTS?
THANK YOU VERY MUCH.
SO NOW WE WILL TURN THE SECTION
OVER TO OUR CHAIR.
>> THANK YOU TO ALL
COUNCILMEMBERS FOR THEIR VERY
THOROUGH REVIEW AND HELPFUL
DISCUSSION.
WE HAD 14 CONCEPTS TO GO
THROUGH'S WE HAVE THE PRIMARY
REVIEW.
WITH A SUMMARY OF THE CONCEPT IN
THE DISCUSSION.
SO THE FIRST CONCEPT WAS AN IA
AGING SAILOR REPOSITORY WITH
CONTRACT RENEWAL WITH DOCTOR
PETERSON AND DOCTOR BAKER.
>> I'M HAPPY TO GIVE A SUMMARY.
A REQUEST FROM THE DIVISION OF
AGING BIOLOGY FROM MEDICAL
RESEARCH WHICH HELPS TO MAINTAIN
THE NIA AGING REPOSITORY.
AND THEN WITH THAT AGING CELL
REPOSITORY WAS STARTED IN 1974.
THIS WAS A LONG-TERM INITIATIVE
AND HAS A NUMBER OF RENEWALS AND
THAT THE SCOPE WE STARTED THE
REPOSITORY IN THE PURPOSE IS TO
PRODUCE AND CHARACTERIZE AND
DISTRIBUTE HUMAN AND ANIMAL CELL
LINES TO THE COMMUNITY.
CELLS ON THE REPOSITORY
ORIGINATE FROM 42 ANIMAL SPEC
SPECIES, 27 NONHUMAN PRIMATES
THE REPOSITORY HAS OVER 3000
LINES IN THE MAJORITY ARE OF
HUMAN ORIGINS.
AND THOSE WITH HEALTHY HUMANS OF
DIFFERENT AGES AND ABOUT
50 PERCENT OF THE PEOPLE AND ARE
ALSO DIVERSE IN 20 PERCENT ARE
NONWHITE AND EQUALLY
DISTRIBUTED.
SO THE USE OF THE REPOSITORY
WITH AN AVERAGE OF 12000
CELLULAR LINES ARE SENT OUT
EVERY YEAR.
BUT ALSO INTERNATIONALLY MOST
ARE REQUESTED FROM HUMANS AND
THEN TO DISCUSS THE FACT THERE
HAS BEEN AN INCREASE WAS
RESPONSE SO THE REPOSITORY HAS
EXPANDED THE EFFORT IN THE LAST
YEAR TO COLLECT MORE FROM THE
NONHUMAN PRIMATES THERE IS MUCH
LESS INTERESTED IN ANIMAL CELL
LINES TO CONTINUE TO MAINTAIN
THE LINES THAT THEY HAVE BUT NO
PLANS TO EXPAND GREATLY THE
DOMESTIC ANIMAL LINES.
THE PUBLICATIONS FROM THE
RESOURCE HAS BEEN TREMENDOUS BUT
JUST IN THE PAST 3 YEARS 150
PUBLICATIONS BUT THIS REPOSITORY
REALLY ADDRESSES 2 MAJOR GOALS
OF THE AN IA TO PROVIDE
RESOURCES TO THE RESEARCH
COMMUNITY TO ENABLE RESEARCH AND
ALSO INDIRECTLY TO LEAD TO A
BETTER UNDERSTANDING AND TO USE
THESE TO HAVE NEW STRATEGIES TO
PREVENT DISEASE THAT DECLINES
WITH AGE.
THERE WAS GREAT ENTHUSIASM AMONG
THE COUNCIL TO SUPPORT THE
RENEWAL A VALUABLE RESOURCE VERY
WELL MANAGED AND UTILIZED IN
RESEARCH COMMUNITIES.
WE WERE STRONGLY IN FAVOR.
>> WE WILL HAVE A VOTE AT THE
VERY END OF ALL OF THEM SO NOW
WE WILL MOVE TO THE SECOND.
THE VOLUNTEER MONITORING THIS IS
ALSO THE CONTRACT RENEWAL AND
DOCTOR BAKER PLEASE DESCRIBE THE
CONCEPT AND THE DISCUSSION.
>> IT'S INTERESTING IT'S VERY
MUCH RELATED TO WHAT WAS JUST
INTRODUCED ABOUT CELLS BUT NOW
IT IS AGING VERTEX THAT IS
DISTRIBUTED THROUGH NIA OVER TO
VARIOUS INSTITUTIONS THIS MEANS
WE KNOW WHAT IS GOING ON AND
THAT WE CAN BRING THEM INTO THE
FACILITIES AND ALL OF THOSE
TYPES OF ISSUES.
SO THIS IS THAT IT IS OUTSOURCED
IN TERMS OF MONITORING THE
PATHOLOGY THOSE THAT ARE
ACQUIRED AND WITH THE OWN
RESEARCH PROGRAMS THE ALL MIDDLE
SENTINEL PROGRAM AND THEN THIS
CONTRACT IT IS USEFUL AND THEN
DOING A COMPLETE EXAMINATION OF
A HANDFUL OF ANIMALS WITH THE
CHANGE PATHOLOGY COLLECTING
BLOOD AND NECROPSY AND
QUESTIONABLE TISSUES.
AND THEN TO BE ISOLATED AND
LOOKING IF THERE ARE PROTO-
SITES IN THE ANIMALS.
AND NOW A RESOURCE TO UNDERSTAND
WHAT IS GOING ON WITH THE MICE
AND RATS IS A START TO
DISTRIBUTE TO OTHERS TO IMPORT
INTO FACILITIES.
THIS IS AN EXTREMELY IMPORTANT
RESOURCE AND IT MAKES SENSE TO
RENEW THE CONTRACT WITH
OVERWHELMING SUPPORT WITH THE
COMMITTEE YESTERDAY.
>> THE NEXT CONCEPT IS THE
IMPACT OF STRESSORS ON THE
BIOLOGICAL MECHANISMS OF AGING
AND OTHER ASSOCIATED OUTCOMES
AND EXPERIMENTAL MODEL SYSTEMS.
DOCTOR MANLEY PLEASE DESCRIBE
THE CONCEPT AND DISCUSSION.
>> YES THIS CONCEPT CLEARANCE
PROVIDES A RATIONALE FOR A SET
OF APPLICATION THROUGH THE
MECHANISM CALLED ARE 61, OR 33
APPLICATION.
AND THE GOAL IS TO HAVE THE
IMPACT OF MIDLIFE STRESSORS WITH
AN EXPERIMENTAL MODEL SYSTEM MAY
ALREADY KNOW PRETTY WELL THAT
EXTERNAL STRESSORS CAN AFFECT
HEALTH AND ACCELERATE IN
BIOLOGICAL AGING THAT MOST OF
THE STUDIES PROVIDING THIS
FOUNDATION ARE EITHER
OBSERVATIONAL OR WITH THE
EXPERIMENTAL SETTINGS TO FOCUS
ON EXPOSURES AND SHORT-TERM
OUTCOMES.
AND ARE IN TIGHTLY CONTROLLED
CONDITIONS.
SO BIOLOGICAL HALLMARKS OF AGING
AND THEN BY THE MODEL SYSTEMS
THAT IN VITRO SYSTEM BUT ALSO
LABORATORY IN TO BE
CHARACTERIZED WERE DOMESTICATED
WITH POPULATIONS.
THE EXPERIMENTS WITHIN THOSE
POPULATIONS ARE TIGHTLY
CONTROLLED.
BUT THAT'S NOT THE WAY IT
HAPPENS IN THE REAL WORLD WITH
THOSE INTERACTIONS ARE BETWEEN
STRESSORS.
THESE INTERACTIONS ARE IMPORTANT
TO UNDERSTAND TO KNOW IF IT
OCCURS IN MIDLIFE.
THE WORKSHOP APRIL 2023 AND WITH
THE HALLMARKS OF AGING AND
OPENING THE WAY FOR POST
DEVELOPMENT STRESSORS SO TO
UNDERSTAND THE MALLEABLE
PROCESSES.
AND WITH THAT TWO-PHASE
APPLICATION AND THE SECOND PHASE
IS CONTINGENT ON ADMINISTRATIVE
REVIEW.
AND THE NOFO WORD HAVE STUDIES
TESTING STRESSORS IN A SINGLE
MODEL SYSTEM OR MULTIPLE MODEL
SYSTEMS.
THE APPLICATION ORIGINALLY
ENCOURAGE MULTIDISCIPLINARY
DISCUSSIONS WHETHER JUST BY
VIRTUE OF THAT BEING A CRITICAL
ROLE AND WHETHER THE IS
ENCOURAGED AND IT SHOULD BE
REQUIRED AND IN ADDITION TO
AGREE WITH THE IMPORTANCE OF
THIS FUNDING APPLICATION THERE
IS ALSO DISCUSSION OF A MISSED
OPPORTUNITY WITHIN THE NOFO
BETWEEN HEALTH DISPARITIES AND
THE STRESSORS THAT MIGHT BE
STUDIED WE TALKED ABOUT HOW
DIFFICULT IT IS TO PUT THE HUMAN
WORLD OF DISPARITIES INTO THE
ANIMAL WORLD OF STRESSORS BUT
ULTIMATELY THERE MAY BE
OPPORTUNITIES TO THINK ABOUT
THAT AND HAVE THAT BE A PART OF
THE APPLICATION.
SO WITH THAT WE ENTHUSIASTICALLY
SUPPORT THIS CONCEPT.
>> WE WILL MOVE ON TO THE NEXT
SET OF CONCEPTS.
SAID ON INTERDISCIPLINARY
BEHAVIOR FOCUSED ON PROMOTING
THE USE OF THE NIH STAGE MODEL
AND COGNITIVE DATA FROM THE
HEALTH AND RETIREMENT STUDY AND
TO HARMONIZE COGNITIVE
ASSESSMENT PROTOCOL ON AGING FOR
CROSS NATIONAL DATA ANALYSIS.
PLEASE SUMMARIZE THE CONCEPT.
>> THANK YOU IT IS A PROPOSAL TO
USE THE R 25 MECHANISM USED IN A
NUMBER OF DIFFERENT WAYS BUT TO
USE IT TO ADVANCE RESEARCH IN
SPECIFIC AREAS WHERE NIA IS
INVESTING IN OPPORTUNITIES OR
HAS A DESIRE TO EXPAND A
FRAMEWORK IT IS A BLUEPRINT WITH
INTERVENTION TRIALS AND THE IDEA
TO THINK ABOUT BEHAVIORAL
INTERVENTIONS TO WORK WITH AND
THAT MODEL AND THEIR PLANS.
AND THE OTHER TOPIC IS TRAINED
TO DO SECONDARY ANALYSIS WITH
THE INTERNATIONAL COMMUNITY AND
THOSE CASE STUDIES THAT HAVE
RICHER MEASUREMENT.
THERE ARE GREAT OPPORTUNITIES
FOR INNOVATIVE RESEARCH BECAUSE
WHAT MOST OF THE STUDIES HAVE IN
THE POLICY VARIATIONS ACROSS
DIFFERENT CONTEXT AND NATIONAL
ANALYSIS OFFERS POTENTIAL TO
LEARN NEW THINGS SO WITH THE
ENTHUSIASM FOR BOTH OF THESE IT
IS SO DIFFERENT TO REQUIRE SUCH
A DIFFERENT SET UP AND DESIGN
FOR STUDENTS TO BE RECRUITED WE
FELT THEY SHOULD BE SEPARATE
FUNDING OPPORTUNITIES AND NOT
TRY TO SQUEEZE THEM INTO 1 THAT
WERE NOT ADEQUATELY ADDRESS
EITHER SPECIFICALLY.
>> WE WILL MOVE ON TO THE NEXT
GROUP WITH THE TRANSLATIONAL
AGING RESEARCH PRECLINICAL AND
EARLY PHASE HUMAN STUDIES.
PLEASE PRESENT THE CONCEPT
DOCTOR BAKER.
>> THIS PARTICULAR CONCEPT IS BY
THE TRANSLATION RESEARCH WORKING
GROUP THAT IS THE YOU AGE 2 AND
3 TO SUPPORT CATEGORIES OF
PROJECTS IN THE CONVENTIONAL
PATHWAY SUCH AS CHEMICAL
MOLECULAR ENTITIES WITH ENTRY
POINTS SUCH AS SCREENING AND
THROUGH LATE STAGE PRECLINICAL
DEVELOPMENT AND THE SECOND
APPROACH THROUGH DATA DRIVEN
THROUGH SUBSEQUENT VALIDATION
WITH THE GENERATION PROOF OF
CONCEPT DATA WITH IN VIVO AND IN
VITRO EXPERIMENTAL SYSTEMS AND
THEN THE INVESTIGATIVE TEAMS
WITH MULTIDISCIPLINARY WITH THE
TRANSLATIONAL RESEARCH PROJECT
THROUGH THE PIPELINE THROUGH
BASIC COMPUTATIONAL MEDICINAL
CHEMISTRY AND PRECLINICAL DRUG
DEVELOPMENT EXPERTISE.
SO OBVIOUSLY THIS IS
MULTIDISCIPLINARY WITH THOSE
THAT ARE POTENTIALLY ACADEMIC
AND NONPROFIT ENTITIES TO
ACHIEVE THE REQUISITE
EXPERTISE.
ULTIMATELY THE COMMITTEE FELT
THE TOPICS WERE VERY RELEVANT
FOR AGE-RELATED RESEARCH.
IT'S VERY IMPORTANT FOR MOVING
THINGS INTO THE NEXT STAGE WE
CAN THINK ABOUT WITH SOME TYPE
OF CLINICAL UTILITY AND TO BE
SUPPORTIVE OF THIS PARTICULAR
CONCEPT.
>> THE NEXT CONCEPT IS RENEWAL
OF GRANTS FOR EARLY MEDICAL
SURGICAL SPECIALIST TRANSITION
TO AGING RESEARCH.
PLEASE PRESENT THE CONCEPT AND
DISCUSSION.
>> GEMSSTAR IS WITH ESTABLISHING
A TRACK RECORD IN A FOCUSED
RESEARCH ON AGING.
THE OVERALL GOAL IS TO ENCOURAGE
THEM TO HAVE LONG-TERM
COMMITMENT TO THE AGING FIELD AS
WELL AS PURSUE CAREER A RESEARCH
FOCUSED CAREER ON AGING RESEA
RESEARCH.
IT PROVIDES A MECHANISM GRANT AT
THE SECTION IS AGING WITH
PRIMARY CLINICAL SPECIALTY AND
ALSO PROFESSIONAL DEVELOPMENT
PLAN AND ALSO A CONFERENCE THAT
IS PROVIDED TO PROVIDE SUPPORT
AS THE HIGH POINTS OF THE
PROGRAM THEY HAVE BEEN IN PLACE
NOW FOR YEARS TO HELP LAUNCH THE
CAREERS OF 221 AND IT HAS BEEN
VERY SUCCESSFUL AND RESEARCH
CAREERS AND SUCCESSFUL ACADEMIC
AND LEADERSHIP ROLES IN THEIR
FIELDS ON THE DISCUSSION WITH
THE SUPPORT FOR THE PROGRAM AND
NO QUESTION THAT WAS HIGHLY
SUCCESSFUL THERE WERE SOME
RECOMMENDATIONS PROVIDED TO TRY
TO ENHANCE THAT TRAINING THAT IS
PROVIDED AND THEN TO ENSURE
ADEQUATE PROJECT SUPPORT THAN
THE GRANTS TO BE USED FOR SALARY
SUPPORT AND CONTINUING TO
ENHANCE THE PROGRAM RESPONSE OF
FEEDBACK TO THE CANDIDATES AND
TO ASSURE DIVERSITY.
THANK YOU SO MUCH.
>> THE NEXT CONCEPT IS MENTORED
CAREER DEVELOPMENT AND
ENHANCEMENT AWARD TO BUILD CROSS
DISCIPLINARY KNOWLEDGE AND
SKILLS FOR COMPARATIVE STUDIES
OF HUMAN AND NONHUMAN PRIMATE
SPECIES WITH DIFFERING
LIFESPANS.
DOCTOR PETERSON PLEASE PRESENT
THE COMMENTS.
>> THIS CONCEPT IS AIMED AT
DEVELOPING AND ATTRACTING BOTH
EARLY CAREER SCIENTIST TO EXPAND
THE NUMBER OF INVESTIGATORS
ACROSS BASIC SCIENCE AND
VETERINARY SCIENCE AND CLINICAL
SCIENCE IT IS EXPERTISE THAT
THAT COMPARATIVE STUDY THAT
CONTRIBUTES TO DIFFERENCES IN
LIFESPANS IF YOU LOOK AT PRIMATE
SPECIES THE LIFESPAN IS
TREMENDOUS AND WE WENT TO
UNDERSTAND THAT AS A GOAL OF THE
NEW INITIATIVE.
2 DIFFERENT TARGETED RESEARCH
WORKS WERE REQUESTED 1 IS FOR
VERY EARLY CAREER INVESTIGATORS
AND THEN THE SECOND TO REQUESTED
IS MORE MID-LEVEL TO COME INTO
THE FIELD OF AGING AND THE FIELD
OF AGING THROUGH RESEARCH CAREER
ENHANCEMENT AWARD.
AS I SAID THE GERONTOLOGY
DIVISION WAS AT THIS BUT THE
OTHER 3 DIVISIONS ARE SUPPORTIVE
AND A PART OF THIS REQUEST.
THIS AREA IS COMPLEX AND
EXCITING.
THE RANGE OF THE POTENTIAL
CONTRIBUTORS TO THE DIFFERENCES
OF PRIMATE SPECIES LIFESPANS
REQUIRE EXPERIENCE AND EXPERTISE
SUCH A BROAD ARRAY OF AREAS
INCLUDING RESEARCHERS AND HUMAN
LONGEVITY AND COMPARATIVE
BIOLOGY, EVOLUTIONARY
GENETICS, ANTHROPOLOGY, AS WELL
AS BASIC CLINICAL SCIENTIST
ALREADY IN THE FIELD OF AGING.
AND THIS IS REQUIRED TO DEVELOP
TO IDENTIFY CONTRIBUTING FACT
FACTORS.
THE REQUEST FOR THESE AWARDS
COMPLEMENT THOSE THAT WERE
ISSUED FISCAL YEAR 24 AND
APPROVED BY THE COUNCIL
PREVIOUSLY AND THAT IS 1 IN THE
NEW AREA OF COMPARATIVE PRIMATE
BIOLOGY THAT IS APPROVED AND
REQUESTED AND THEN THE SECOND
RFA DESIGNED TO FUND THE
INFRASTRUCTURE GRANT THAT IS
NETWORKING TO HELP COORDINATE
THOSE FUNDED R 01.
SO THE COUNCIL IN GENERAL IS
VERY SUPPORTIVE AND IT'S
ESSENTIAL FROM ALL OF THE
RELEVANT DIFFERENT AREAS OF
BIOLOGY MANY OF WHOM WERE NOT
NORMALLY THINK OF AN AGE IS A
PARTICULAR FUNDING SOURCE THIS
IS THE IDEA UNNECESSARY THAT THE
AN EYE HAS -- -- HAVE IN THOSE
METHODS TO ATTRACT PEOPLE IN
DIFFERENT FIELDS.
THIS REQUIRES BUILDING THE
INTERDISCIPLINARY RESEARCH TEAM
AND THEN TO BE VERY SUPPORTIVE
OF THIS IDEA TO BUILD THE
PRIMATE BIOLOGY AND LONGEVITY.
IT IS VERY EARLY ON IN THE
DEVELOPMENT OF THIS FIELD THAT
THE RF A 4801 HAVE THE POTENTIAL
TO BUILD THE FOUNDATION FOR THE
NEW FIELD AND PROVIDE
INFRASTRUCTURE TO ALLOW
INVESTIGATORS TO DEVELOP THEIR
OWN DISCIPLINARY TEAMS BUT WE
FELT AS A TEAM AND WHAT WE
DISCUSSED BECAUSE THIS IS A NEW
AREA AND WITH THAT WE THOUGHT IT
MIGHT BE PREMATURE TO THINK A
YOUNG INVESTIGATOR IN THE AREA
OUTSIDE OF THIS COULD IN FACT
RIGHT NOW WITH NO INFRASTRUCTURE
TO DO INTERDISCIPLINARY TEAMS TO
REACH OUT TO OTHER AREAS AND
HAVING A TRACK RECORD SO WE
THOUGHT THAT 1 POSSIBILITY WOULD
BE TO SPLIT THIS INTO 2 SO NOW
IT IS ISSUED FOR THE MIDCAREER
FOR ESTABLISHED INVESTIGATORS
WHO WANT TO BROADEN OUT INTO
PRIMATE BIOLOGY WHILE ALLOWING
THE FIELD TO DEVELOP SO THERE IS
A FOUNDATION AND THOSE COULD
THOSE COLLABORATIVE
OPPORTUNITIES AS PEOPLE BECOME
ESTABLISHED IT MIGHT BE WISE TO
HOLD OFF ON THOSE AND THEN TO
DEVELOP TO PUT MORE SUPPORT ON
THESE INVESTIGATORS TO ESTABLISH
THE INTERDISCIPLINARY
COLLABORATIVE TEAMS.
>> THANK YOU FOR REVIEWING THAT
AND THE CONCEPT OF THE COMMENTS
UP NEXT UNDERSTANDING THE
MECHANISMS WITH AGE-RELATED
CHANGES WITH THE BIOMECHANICS
INCREASING THE METABOLIC COST OF
WALKING.
SO BECAUSE MOBILITY AND
DYSFUNCTION TALKS ABOUT A
QUARTER OF THOSE OVER THE AGE OF
65 REPRESENTS A MAJOR HEALTH
PROBLEM AND THEN TO BE
ASSOCIATED STRENGTH, POWER
BALANCE, JOINT MOBILITY AND ALL
OF THAT WILL IMPACT BIOMECHANICS
BARRIER TO EFFECTIVE TARGETING
FOR PREVENTION HAS BEEN A LACK
OF UNDERSTANDING ON THESE
RELATED CHANGES OF THE
NEUROMUSCULAR AND MUSCLE
SYSTEMS.
TO ADDRESS THE RESEARCH GAPS
LEADING A WORKSHOP
SEPTEMBER 2021 THAT LED TO THE
CURRENT RFA.
SUPPORTING RESEARCH STUDIES
USING THE R 01 MECHANISM WITH
MULTIDISCIPLINARY TEAMS TO
EMPLOY COMPLEX INNOVATIVE
APPROACHES SPECIFICALLY
SUPPORTING STUDIES TO BETTER
UNDERSTAND THE MECHANISMS
UNDERLYING COMPENSATORY POSTURE
STRATEGIES THAT CONTRIBUTE TO
SLOWER WALKING SPEED AND
FATIGABILITY.
THE GOAL WAS TO EXAMINE MULTIPLE
SYSTEMS INCLUDING
MUSCLES, TENDONS AND THE AREAS
OF INTEREST INCLUDE THE EFFECTS
OF CNS AND MUSCULAR
CHANGES, SCALE IT OR
COMPUTATIONAL MODELING AND
SIMULATION AND CHANGES OF TISSUE
STRUCTURE AND FUNCTION.
THE COLLABORATIONS ARE
ENCOURAGED WITH NO INTER-
DIVISION ARE PART OF THE
PROPOSAL A JUSTIFICATION WOULD
BE NEEDED THIS WAS IMPORTANT AND
TIMELY THAT IS A COSTLY PROBLEM
AND KEY TO THE SUCCESS OF THE
PROPOSAL AND TO BE VERY
ENTHUSIASTIC MOVING FORWARD.
WE WILL GO AHEAD WITH THE NEXT
CONCEPT REGARDING THE RENEWAL OF
THE UPPER OLDER AMERICAN
INDEPENDENT CENTERS.
PLEASE PRESENT THE CONCEPT.
>> TO IS CONCEPT WITH THE END OR
PARENT -- -- INDEPENDENT OLDER
AMERICANS CENTER PROGRAM IT IS
SUPPORTED BY THE OCCURRING
GRANTS IN EXISTENCE FOR DECADES
AND TO FOCUS THE RESEARCH ON THE
PHYSICAL INDEPENDENCE.
IT IS WELL DOCUMENTED THE LOSS
OF MOBILITY AND VARIOUS DISEASES
THAT AFFECT THE ABILITY AND
SIGNIFICANTLY REDUCE THE QUALITY
OF LIFE AND ALSO HAVE
CONSEQUENCES AND 1 OF THE MOST
COMMON CAUSE IN THE UNITED
STATES AND 14 MILLION AMERICANS
EACH YEAR IS MORTALITY FROM A
FALSE ALARM HAS INCREASED BY
41 PERCENT.
SO THE FOCUS OF THE PRESENTERS
IS ON THE THEORY OF AGING
RESEARCH OVER THE YEARS RESEARCH
AND UNDERSTANDING AND BETTER
PHYSIOLOGY AND LOSS OF FUNCTION
AND MOBILITY AND ALSO HOW TO
TREAT AND PRESENT THE ISSUE.
OVER THE YEARS TO BE VERY
PRODUCTIVE AND TO PUBLISH THE
ORIGINAL FINDINGS AND HAVE
CONDUCTED A NUMBER LIKE STRIDE
AND ENERGIZE AND THEN INTO A
LARGE RESEARCH PROGRAM AND THEN
TO ATTRACT YOUNG SCIENTIST
GENERATING A PIPELINE.
AND ALSO COLLABORATE WITH
PROGRAMS AND THESE INCLUDE THE
SYSTEMS RESEARCH NETWORK.
THEY HAVE THE RESEARCH EDUCATION
COMPONENT THE COMPONENT.
SO OVERALL IT BECOMES A VERY
SUPPORTIVE OF THE CONCEPT TO
BETTER TRANSLATE THE FINDINGS
AND TO IMPROVE THE CARE OF AND
WORKING HARD TO IMPROVE THE
RESEARCH FINDINGS FROM THIS
PROGRAM.
ALSO UNANIMOUS RECOMMENDATION
FOR INCREASE THE NUMBER AND ALSO
TO INCREASE THE ANNUAL BUDGET.
WE UNDERSTAND THE MOVING FORWARD
IN THIS IS WITH THE BUDGET IS
REALIZED FROM THE PROGRAM.
AND I THINK YOU.
WE WILL NOW MOVE TO THE LAST SET
OF CONCEPTS INVESTIGATED
MITOCHONDRIAL NUCLEAR
COMMUNICATION AND BRAIN AGING.
PLEASE SUMMARIZE THE CONCEPT AND
COMMENTS.
>> WITH THE MITOCHONDRIA
FUNCTION.
AS THE CREATOR AND THEN TO
COMPLETE A DIVERSE SET OF
BIOLOGIC FUNCTIONS AND ALL THAT
GENOMIC DNA AND ALSO SEARCHES
THROUGH OTHER PROTEINS AND ALSO
REQUIRES OTHER PROTEINS TO
CODIFY THE DNA SO THAT
COMMUNICATION BETWEEN THE
MITOCHONDRIA AND THE NUCLEUS IS
MITOCHONDRIAL FUNCTION AND ALSO
THE PROCESS BOTH PHYSIOLOGICAL
PREVENTION AND IN SOME CASE AS A
DISEASE.
SO THEN TO BE IDENTIFIED LEADING
TO SPECIES AND OTHER HEADLINES
AND TO BE METABOLIZED TO
PROFOUNDLY IMPACT THE
MODIFICATION OF PROTEINS AND
RESEARCHERS ARE BEGINNING TO
EXPLORE AND THE GENE REGULATION
AND EXPRESSION AND THEN TO
CONSIDER AS A METABOLIC TRANSFER
OF AGING.
SO IT IS THAT COMMUNICATION
LETTING THAT PLAY A KEY ROLE.
SO WITH THE COMMUNICATION IS THE
COMPLEXITY THAT IS STARTED.
IT IS THE DYNAMIC OF MANY
DIFFERENT STAGES AND THE NUMBER
OF CHALLENGES SO THEN THIS
PROPOSAL TO HELP STIMULATE ALL
THOSE SPECIFICALLY AND THEN TO
FURTHER STUDY THE COMMUNICATION
AND THEN TO EXPLORE AT ONCE AND
EXTEND WITH THE CELLULAR
FUNCTION.
AND THE PROPOSAL AND WITH THE
EXISTING CSR IS COMPLETE FROM
THE MITOCHONDRIA AND THE FUNDING
ALLOCATION THAT IS PROPOSED SO
IT IS HIGHLIGHTED TO THE NIA
GOALS AND ACTIVITIES.
SO WITH THE CONCEPT DISCUSSION A
WELL-DESIGNED SUPPORT.
>> THANK YOU.
THE NEXT IS THE BRAIN CELLS
SUBTYPES INDICATED OF AGING AND
DOCTOR BAKER PLEASE REVIEW THE
CONCEPT AND COMMENTS.
>> THE FOCUS OF THIS PARTICULAR
NOFO CONCEPT WAS UTILIZATION OF
NEW ELITE APOLOGY TO ADDRESS
QUESTIONS AND UNDERSTAND THE
ROLE OF SPECIFIC BRAIN CELLS
SUBTYPES MANY LARGE-SCALE
EFFORTS CURRENTLY FUNDED AND
IDENTIFYING THE PARTICULAR CELL
TYPES AND GENERATING HIGH
QUALITY SINGLE CELL AT THE
GENOMIC AND EPIGENETIC SITES
BOTH HUMAN TISSUE AND ORGANISMS
DURING NORMAL AGING AND
PROGRESSION FROM THE SUPPORTED
PROJECTS THAT HAVE UNCOVERED
DISEASES ACROSS ALL MAJOR CELL
TYPES TO IDENTIFY INCLUDING
NEURONS AND VASCULAR CELLS.
BUT IT IS NOT EXACTLY CLEAR HOW
THESE CHANGES CONTRIBUTE TO
DEFICITS OR BRAIN FUNCTIONS THE
GOAL IS TO DEVELOP NODULES -- --
NOVEL STRATEGIES TO BE
IMPLICATED TO IMPLEMENT THE
TOOLS TO THE MECHANISTIC
HYPOTHESIS WITH THE
BREAKTHROUGHS OF MECHANISTIC
RESEARCH AND PRECLINICAL STUDIES
TO ACCOMPLISH THIS THE PLAN WAS
TO ACHIEVE 2 MAJOR OBJECTIVES TO
WITH THE SUBTYPES AND WITH THE
EPIGENETIC'S AND THE SUBTYPES
LIKELY TO HAVE A ROLE IN THOSE
TO VERIFY AND THOSE WOULD ALSO
BE SUPPORTED AND THEN TO ACHIEVE
WITH THAT TARGETING AND THE
BRAINS FROM ANIMAL MODELS.
THE SECOND IS TO HAVE THE
ENHANCER TOOLS WITH THE SUBTYPES
TO ADDRESS THE MECHANISTIC
HYPOTHESIS TO UNCOVER THE ROLE
OF DISEASE PROGRESSION AND THOSE
THAT ARE LOADED INTO THE AV
MODEL IT IS USEFUL FOR DIGESTING
THE FUNCTION AND REPRESSION
INCLUDING LIKE THE FLUORESCENT
PROTEINS TRANSCRIPTION FACTORS
AND OTHER ELEMENTS.
THIS IS A VERY RELEVANT VIEW
WITH A LOT OF OPPORTUNITY TO
BYPASS THE LIMITATIONS OF
GENETIC APPROACHES THE COMMITTEE
WAS HIGHLY SUPPORTIVE OF THE
OVERALL CONCEPT SPENT THE NEXT
CONCEPT IS THE DRUG DEVELOPMENT
PROGRAM.
PLEASE GO AHEAD.
>> THIS IS A RENEWAL OF YEAR 1
DATABASE PROGRAM FOR DRUG
DEVELOPMENT.
IT WAS ORIGINALLY LAUNCHED 2006
AND THE GOAL WAS TO INCREASE THE
NUMBER OF EMERGING CANDIDATES TO
INCREASE THE DIVERSITY OF
APPROACHES.
THIS PROGRAM FUNDS A BROADER
RANGE OF THE PIPELINE FROM EARLY
STAGES SUCH AS MEDICINAL
CHEMISTRY AND THERAPEUTIC AGENTS
WITH ABSORPTION AND OTHER
FEATURES AND EFFICACY AND
PRECLINICAL MODELS OF
FORMULATION.
CHEMICAL SYNTHESIS AT THE GMP
LEVEL REQUIRED FOR A CLINICAL
TRIAL SUCH AS LARGE ANIMAL
TOXICITY ALL THE WAY INTO PHASE
HUMAN TESTING.
CLINICAL MILESTONES ALONG THE
PATHWAY TO THERAPEUTIC
DEVELOPMENT.
TODAY IT IS GREAT TO HAVE
QUANTITATIVE DATA PER GO 45 YEAR
1 PROJECTS HAVE BEEN FUNDED AND
12 OF THESE HAVE RESULTED IN
CANDIDATE THERAPEUTICS MAKING IT
TO HUMAN TRIALS.
THAT IS AN OPPRESSIVE RATIO.
IF YOU REVIEW DRUG DEVELOPMENT
AND CMS DISEASES INCLUDING
ALZHEIMER'S YOU SEE A MASSIVE
DROP OFF RATE SO 12 OUT OF 45 IS
IMPRESSIVE SOME OF THESE MAKE IT
INTO PHASE 2 TRIALS.
ALSO A STRONG POINT A MILESTONE
DRIVEN PROGRAM AND THAT IS
EXECUTED FORTUNATELY TO OTHER
PROJECTS HAD TO BE TERMINATED
DUE TO NOT MAKING THE
MILESTONES.
THE RENEWAL OF THIS PROGRAM WILL
FUND A SIMILAR PIPELINE AND
EXPAND THE NUMBER OF CANDIDATES
AND THE DIVERSITY.
IT IS IMPORTANT BECAUSE OTHER
PROGRAMS ARE IDENTIFYING TARGETS
SO THIS WILL ENABLE THE
DEVELOPMENT OF AGENTS TO GO
AFTER THAT EMERGING LARGE NUMBER
OF TARGETS AND THEN TO SUPPORT
DEVELOPMENT WITH NEW TARGETS ARE
IDENTIFIED AND THEN TO ALSO
SERVE AS NEW BRAIN IMAGING AND
THE CAPABILITY TO DO 2 CRITICAL
THINGS TO ALLOW PRECISION AND
MEDICAL APPROACH AND WHAT THEIR
BEES MIGHT BE THE BEST AND ALSO
TO DOCUMENT TARGET ENGAGEMENT.
SO THIS PROGRAM WE THINK IS
HIGHLY SUCCESSFUL AND SHOULD BE
RENEWED.
>> THANK YOU.
WE WILL NOW MOVE TO THE NEXT
CONCEPT OF COGNITIVE DECLINE OF
INDIVIDUALS WITHIN THE AUTISM
SPECTRUM.
SO PLEASE PRESENT THE CONCEPT
AND THE COMMENTS.
>> THIS IS A NEW CONCEPT THAT
SEEKS TO ESTABLISH COHORTS WITH
AUTISM SPECTRUM DISORDER AND TO
COLLECT PROSPECTIVE DATA TO
UNDERSTAND THE PHYSIOLOGY IS
VERY COMPLEX DEVELOPMENTAL
DISORDER.
IF APPROVED THEN FOR THE FIRST
TIME IT WOULD ALLOW AN IA TO
LAUNCH SYSTEMATIC STUDIES AND
THEN TO DEVELOP MARKERS FOR THIS
IMPORTANT DISORDER.
SO IT IS QUITE COMMON AND IS
SIMULATED IN CHILDREN ACROSS
UNITED STATES AND IT SEEMS TO BE
HIGHER AND BLACKS AND HISPANICS
AND ASIAN AND PACIFIC ISLANDERS
IT IS A FACETED DISEASE WITH
SIGNIFICANT HETEROGENEITY AND
THERE'S EPIDEMIOLOGICAL STUDIES
AND THEN THEY HAVE INCREASED
RISK OF DEMENTIA AND ALSO TO
HAVE SOME COGNITIVE DEFICITS
WITH THE PROCESSING SPEED AND
STUDIES TO HAVE THAT FUNCTIONAL
CONNECTIVITY SO THERE IS SOME
EVIDENCE BUT IT IS PRELIMINARY
AND NEEDS TO BE CONFIRMED.
PEOPLE WITH ASD WITH THESE
PATHWAYS IN THEIR BRAINS AND
THERE COULD BE SOME MECHANISMS
SO OVERALL THERE IS VERY LIMITED
RESEARCH AND THE BIOGENETIC'S
WITH THE HETEROGENEITY AND THE
BIOMARKERS WE HAVE FOUND THIS IS
A TIMELY PROPOSAL TO GENERATE
NEW INFORMATION THAT IS QUITE
COMMON AND ALSO WITH DEMENTIA
AND OVERALL IT IS HIGHLY
SUPPORTIVE AND IT'S A VERY
TIMELY CONCEPT.
THANK YOU FOR PROVING IT.
>> AND THE FINAL CONCEPT
DECIPHERING THE IMPACT OF RNA
MODIFICATION ON BRAIN AGING AND
A/D / ADR D.
PLEASE REVIEW THE CONCEPT AND
COMMENTS.
>> THE CHEMICAL MODIFICATION OF
RNA HAS BEEN DOCUMENTED OVER THE
YEARS WITH THAT GENOMIC
TECHNOLOGY SO SO FAR TO HAVE
THAT DISTINCT MODIFICATION HAS
BEEN IDENTIFIED AND WITH THE
HOMEOSTASIS OF THESE COURSES
THERE IS A BRILLIANT
RECOMMENDATION THAT HAS DIRECT
EFFECTS OF PHYSIOLOGICAL
PROCESSES AND IT DOES INDICATE
THAT IT IS A DYSFUNCTION AND IT
IS IMPLICATING WITH THE
DEGENERATING DISORDER HOWEVER
THE DIVERSITY OF THIS IS
EXPLORED.
SO FAR DEVOTED TO THE
MODIFICATIONS SO IT IS THE
SIGNIFICANCE OF THE
MODIFICATIONS IS JUST BEGINNING
TO BE APPROACHED AND WITH THIS
MODIFICATION THAT IS EMERGING
WITH THE BIOMARKERS AND IN THE
FUNCTIONAL ROLES IN THE
RELATIONSHIP WITH THE PROCESSOR
SO I AM OPTIMISTIC BUT WITH THE
REGULATION AND THROUGH THAT
PROCESS AND THEN TO FINE-TUNE
THE REGULATION AND UNDERSTAND
THE DISEASE AND TO INFORM NEW
STRATEGIES.
SO WITH THE BACKGROUND AND THE
PROPOSAL IS TO STIMULATE
RESEARCH WITH THE MODIFICATION
AND THE RNA MODIFICATION WITH
POTENTIAL TARGETS.
SO THERE ARE SEVERAL AREAS OF
INTEREST TO IDENTIFY THIS
PROGRAM AND THEN IT IS SHARED
AND THEY AN IA SUPPORT.
SO THAT MECHANISM AND THIS IS
CLEARLY HIGHLY RELEVANT TO THE
GOALS AND OBJECTIVES SO TO
DISCUSS WITH THE COUNCIL HOW DO
WE SUPPORT.
THANK YOU.
>> AGAIN THANK YOU TO THE
COUNCIL FOR THE VERY THOUGHTFUL
REVIEWS AND COMMENTS.
AT THIS POINT WE WILL VOTE ON
BLOCK FOR ALL OF THE CONCEPTS.
IF WE CAN SEE A SHOW OF HANDS OR
COMMENTS FOR ALL OF THOSE IN
FAVOR?
CAN WE SEE A SHOW OF HANDS?
ALL OF THOSE WHO DO NOT APPROVE?
IT APPEARS THERE IS ENTHUSIASM
FOR THE CONCEPTS TO MOVE
FORWARD.
AT THIS POINT I WILL SEND IT
BACK.
>> THANK YOU.
THANK YOU FOR SHARING THE WORK
YOU HAVE DONE AND TO ALL
COUNCILMEMBERS FOR THEIR
CRITIQUES AND CONCEPTS AND
DISCUSSION.
AT THIS POINT ON THE AGENDA WILL
HAVE 2 SPEAKERS BUT BEFORE WE
HAVE THAT WE WILL TAKE A QUICK 5
OR 10 MINUTE BREAK.
WE ARE RUNNING A LITTLE BIT LATE
TODAY.
SO JUST BREAK AND TELL
12:10 P.M.
THAT IS EASTERN TIME AND THEN WE
WILL BE BACK TO HEAR FROM THE 2
SPEAKERS.
PLEASE STAY ONLINE AND JUST
YOURSELF TO COME BACK AT 12:10 P.M.
>> THANK YOU FOR THE
INTRODUCTION.
BRING UP THE SIDES.
THANK YOU.
WE WILL GIVE YOU AN OVERVIEW OF
THE MISSION AND VISION AND WITH
THE PARTNERSHIPS IS THE
INVESTIGATION THE CONDITIONS
ACROSS THE LIFESPAN KNOWN AS THE
INCLUDE PROGRAM.
PART OF MY INTRAMURAL RESEARCH
LABORATORIES EFFORTS WITH DOWN
SYNDROME AT THE PRENATAL AND
LIFESPAN.
AND TO TALK ABOUT WHAT IS A VERY
INTERESTING AREA FOR FURTHER
INVESTIGATION THAT IS IN THE
NEONATOLOGY AND GERONTOLOGY
CONNECTION AND ALSO THE AREA
THAT WE COULD COLLABORATE MORE
IN THE FUTURE IS THE LIFESPAN OF
REPRODUCTIVE BIOLOGY IS IN WOMEN
FROM MENARCHE TO MENOPAUSE.
'S WE ARE MORE THAN JUST
PARTNERS BUT JOINED AT THE HIP.
THIS IS THE DAY THAT AND I CHD
ENCOMPASSED AGING'S THIS
LEGISLATION WILL ENCOURAGE
IMAGINATIVE RESEARCH INTO THE
COMPLEX PROCESSES OF HUMAN
DEVELOPMENT FROM CONCEPTION AND
THEN THROUGH THE VOICE OF HIS
SISTER EUNICE KENNEDY SHRIVER
AND THEN AGING WAS SPLIT OFF TO
TAKE THE OPPORTUNITY.
SO WHEN I CAME ON LATE 2016 WE
DID NOT HAVE A STRATEGIC PLAN IN
PLACE ALSO A VERY WORDY MISSION
STATEMENT IT WAS LIKE JAY LENO
QUESTIONING OF PEOPLE ON THE
STREET DO THEY KNOW OUR MISSION
AND NOBODY INCLUDING ME COULD AT
THE TIME.
SO WE FOCUS THAT WITH THAT TO
ENHANCE THE LIVES OF CHILDREN
AND ADOLESCENTS TO OPTIMIZE FOR
ALL.
AND THAT REHABILITATION RESEARCH
AND PEOPLE ARE SOMEWHAT
SURPRISED REHABILITATION FROM
STROKE IN ADULTS AND WE
DEFINITELY OVERLAP SO NOT HAVING
A STRATEGIC PLAN THAT TAKES
ABOUT 2 YEARS TO COME UP WITH A
STRATEGIC PLAN IN 2020 STARTING
WITH 270 AND TAKING IT DOWN TO
5.
SO TO UNDERSTAND THE MOLECULAR
DEVELOPMENT PROMOTING
REPRODUCTIVE HEALTH AND SETTING
THE FOUNDATION FOR HELPING
WELLNESS AND IMPROVING CHILD AND
ADOLESCENT HEALTH AND THE
TRANSITION TO ADULTHOOD WHICH IS
A MAJOR GAP AREA ACROSS NIH AND
THEN ADVANCING SAFE AND
EFFECTIVE THERAPEUTICS FOR
PREGNANT AND LACTATING WOMEN AND
CHILDREN WITH INTELLECTUAL
DISABILITIES.
THEY HEAR THE NAME CHILD HEALTH
AND THAT INCLUDES MEMBERS OF
CONGRESS, THEY THINK WE FIND ALL
OF CHILD HEALTH RESEARCH ACROSS
NIH.
THAT IS NOT TRUE WHEN YOU LOOK
ACROSS AND 8 H IT IS 18 PERCENT
OF CHILD HEALTH RESEARCH WHICH
MEANS A LOT OF OTHER INSTITUTES
HAVE BEEN FUNDED CHILD HEALTH
RESEARCH NOT AN IA BUT OTHERS.
WITHIN OUR OWN PORTFOLIO IT IS
HALF PEDIATRICS, 1 THIRD
REPRODUCTIVE HEALTH WHICH
INCLUDES EVERYTHING FOR
DEVELOPMENT TO PRE- CONCEPTUAL
HEALTH, CONTRACEPTION, PREGNANCY
AND POSTPARTUM HEALTH.
AND THEN 18 PERCENT IS A STRONG
COMMITMENT AND THEN THE NATIONAL
CENTER FOR MEDICAL
REHABILITATION RESEARCH.
OF COURSE NAME FOR PRESIDENT
KENNEDY'S SISTER AND A MAJOR
FORCE.
IN FACT THE BIOGRAPHY MAKES THE
CASE THAT SHE WOULD HAVE BEEN
PRESIDENT IF THE ARROW WAS
DIFFERENT.
A LITTLE UPDATE ON INCLUDE WE
ARE STRONG PARTNERS WITH AN IA
INCLUDING PROGRAM LAUNCHED IN
2018 TO INCREASE THE RESEARCH
PORTFOLIO IN DOWN SYNDROME TO
ADDRESS THE HEALTH AND QUALITY
OF LIFE FOR PEOPLE WHO HAVE DOWN
SYNDROME.
THE CONDITIONS WE ARE FOCUSED ON
IS A COMBINATION OF CONDITIONS
MORE PREVALENT IN PEOPLE WITH
DOWN SYNDROME SUCH AS
ALZHEIMER'S, AUTISM, HEART
DISEASE, ET CETERA BUT
SIMULTANEOUSLY LOOKING AT HOW
PEOPLE WITH DOWN SYNDROME ARE
PROTECTED FROM TUMORS.
SO WE COULD LEARN MORE THAT
APPLIES THE KNOWLEDGE OF THE
GENERAL POPULATION.
ALSO INCREASING THE WORKFORCE BY
A TRAINING MORE PEOPLE TO DO
SCIENCE AND ALSO HAVE STRONG
ENGAGEMENT SOME ADVOCATES AND
THOSE FROM DIVERSE BACKGROUNDS.
SO I REMEMBER VERY CLEARLY
BECAUSE WE GOT THIS UNEXPECTED
MESSAGE FROM CONGRESS IN 2017
THAT THERE WAS AN ADVOCATE MR.'S
STEVENS WHO SOLICITED A STANDING
OVATION FROM THE APPROPRIATIONS
COMMITTEE IN THE HOUSE AND MONEY
STARTED TO COME IN TO THE NIH
SPECIFICALLY FOR DOWN SYNDROME
RESEARCH.
IT WAS EASTER WEEKEND 2017 WHERE
ALL STAFF WORK TOGETHER TO HAVE
3 PROGRAM COMPONENTS.
THE FIRST IS BASIC SCIENCE TO
CONDUCT HIGH RISK HIGH REWARD
BASIC SCIENCE AND STUDIES THAT
CENTER ON THE EFFECTS OF
CHROMOSOME 21.
THE SECOND COMPONENT WAS TO
ASSEMBLE LARGER STUDY
POPULATIONS TO UNDERSTAND WHAT
IS GOING ON IN UTERO LIFE TO
ADULT LIFE.
THE THIRD THING WAS TO BE MORE
INCLUSIVE BECAUSE IT WAS MEANT
TO EMPHASIZE INCLUSION OF
INDIVIDUALS WITH DOWN SYNDROME
AND EXISTING AND FUTURE CLINICAL
TRIALS SO PREVIOUSLY THEY WERE
EXCLUDED BECAUSE THEY HAD DOWN
SYNDROME.
IN THE LAST 4 OR 5 FISCAL YEARS
NIH HAS INVESTED $258 MILLION IN
PROJECTS FOR INCLUDE AND IT HAS
TRANSFORMED THE FIELD.
WHAT ARE SOME OF THE
ACHIEVEMENTS SO FAR?
THERE HAS BEEN AN INTENTIONAL
INVESTIGATION AS A RESULT OF
COVID 19 WITH RESULTS OF DOWN
SYNDROME AND THEY WERE AT HIGHER
RISK THAN THOSE WITHOUT.
STUDYING THE CAUSES OF CHILDREN
AND LEUKEMIA THAT IS MORE COMMON
MORE THAN A SOLID TUMOR OF
BREAST CANCER OR COLON CANCER
ALSO NEW COGNITIVE MEASURE IN
THE NIH TOOLBOX DIRECTED TOWARD
CHILDREN WITH DOWN SYNDROME AND
THE EFFORTS AND THEN 1 STUDY IS
DETERMINED IF IT IS AS RELIABLE
AS A HOSPITAL SLEEP A STUDY.
SLEEP APNEA IS A MAJOR PROBLEM
AND THEN TO ASSEMBLE A COHORT OF
ADULTS TO IDENTIFY BIOMARKERS OF
NEURODEGENERATION AND RESILIENCE
FACTOR FOR ALZHEIMER'S DISEASE.
SO I WILL GO BRIEFLY THROUGH THE
SLIDES BECAUSE I'M SURE YOU ARE
FAMILIAR WITH THE BIOMARKER
CONSORTIUM WHICH IS THE ABCD AS
PROJECT 92 INVESTIGATORS ACROSS
19 INSTITUTIONS.
THE BASIC IDEA IS THE BIOLOGICAL
CHANGES UNDERLYING ALZHEIMER'S
DISEASE IN PEOPLE WITH DOWN
SYNDROME AND DEVELOP CLINICAL
BIOMARKERS AS WELL AS THE NON-
DOWN SYNDROME POPULATION THERE
IS A LONGITUDINAL COHORTS THAT
HAS UP TO 600 ADULTS WITH DOWN
SYNDROME.
AGAIN THIS IS FULFILLING SOME OF
THE COMPONENTS OF THE INCLUDE
PROJECT'S.
ANOTHER STUDY IS AMYLOID BURDEN
IN DOWN SYNDROME VERSUS
AUTOSOMAL DOMINANT DISEASE.
THIS IS ANOTHER ABCD S PROJECT
WITH CONTRIBUTIONS FROM INCLUDE
AS WELL AS NAA DOMINANT
INHERITED NETWORK.
WAS LOOKING AT THE TIMING AND
SPATIAL DISTRIBUTION VERSUS A
DAD.
THEY HAVE BEEN DOWNLOADING
SIBLING CONTROL AND THOSE WITH
THE VARIANCE AND 169 CONTROLS
WITH THE RECENT PUBLICATION AND
ALSO PERIODIC MRI AND POSITRON
AND THEY FOUND THE AMYLOID
PLAQUES OCCUR ROUGHLY AT THE
SAME LEVEL OF THOSE IN DOWN
SYNDROME AS THOSE WITH A DAD.
THERE IS THE IMPLICATION THERE
THAT INDIVIDUALS WITH ADD OR
DOWN SYNDROME COULD BENEFIT IN
THE THERAPIES ANOTHER PROJECT
WITH THE EMERGENCE AND DOWN
SYNDROME AND TO REDUCE THE
UNCERTAINTY WITH THE SYMPTOM
ONSET THE LONGITUDINAL
EVALUATION BECAUSE THERE IS SUCH
A WIDE AGE RANGE ONSET OF PEOPLE
AND 192 PARTICIPANTS OVER THE
AGE OF 25 WITH DOWN SYNDROME
HAVE BEEN ENROLLED ALSO GETTING
PERIODIC MRI AND CAT SCAN AND
THEN THE INCREASES ARE 2.5 AFTER
THE ONSET.
SO THIS COULD PROVIDE THE
STRATEGY FOR TEMPORAL
CHARACTERIZATION AND PROGRESSION
THAT IS SPECIFIC IN THE DOWN
SYNDROME POPULATION.
THIS IS A MAJOR CONCERN.
I PARTICIPATE IN THE MEETINGS
AND I WOULD SAY OVERWHELMINGLY
THE PRESENTATIONS ARE ON THE
AGING POPULATION OF DOWN
SYNDROME.
THEY ARE LARGELY POPULATED BY
PEOPLE WHO ARE ADULTS WITH DOWN
SYNDROME AND HAVE GREAT CONCERN
HOW TO TREAT THEM AND TAKE CARE
OF THEM.
1 OF THE GREAT ACHIEVEMENTS OF
THE INCLUDE INITIATIVE WITH THE
PALPABLE INCREASED INTEREST OF
TRAINEES IN DOWN SYNDROME IS NOW
WE HAVE A DATA HUB FUNDED BY
INCLUDE IT IS CLOUD -BASED
DEVELOPED BY THE COORDINATING
CENTER PROVIDING ACCESS TO
LARGE-SCALE DATA RESOURCES THERE
IS 74 OR TERABYTES OF DATA AND
THOUSANDS OF CLINICAL PROFILES
AND GENOMES IN HUNDREDS OF
TRANSCRIPT DOMES AND PROTEINS
THAT METABOLIZE.
WHAT I HAVE FOUND IN MY OWN
RESEARCH IS THERE IS SO MUCH
INFORMATION OUT THERE WITH
PARTICULARLY THE MOUSE MODELS
AND THE RAT MODELS OF DOWN
SYNDROME BUT THERE IS NO WAY TO
COMPARE THEM IN A LARGE SCALE
DATA WAY SO NOW WE ARE FUNDING
ANIMAL DATA AS WELL BUT THE
WHOLE PURPOSE OF THE DATA HUB IS
TO PROVIDE DATA FREELY TO ANYONE
WHO WANTS TO WORK IN THE AREA
BUT ALSO ENCOURAGES
COLLABORATION AND SUPPLYING DATA
TO HAVE A GOOD DATA APPROACH
LOOKING FOR NEW INSIGHTS THE
WEBSITE IS AT THE BOTTOM.
I BELIEVE MY LABORATORY IS THE
ONLY 1 STUDYING DOWN SYNDROME.
I'M NOT AWARE OF ANYBODY ELSE
BUT OUR VISION IS TO TAKE
PRENATAL SCREENING AND DIAGNOSIS
THE FIRST AND SECOND TRIMESTER
OF PREGNANCY BY NONINVASIVE
PRENATAL TEST AND SEQUENCING
FRAGMENTS FROM THE PLACENTA VERY
ACCURATE WE CAN INDEPENDENTLY
AND THE VISION WOULD BE TO
PROVIDE SAFE AND EFFECTIVE
THERAPY TO IMPROVE COGNITION AND
WOMEN CARRYING FETUSES WITH
CONFIRM DOWN SYNDROME.
I KNOW IT SOUNDS A LITTLE CRAZY.
HAD SOME POSITIVE RESULTS.
NOT IN HUMANS BUT IN MICE.
SO IN MY LABORATORY IN THE HUMAN
GENOME INSTITUTE WE ARE TAKING A
TWO-PRONGED APPROACH BACK BEFORE
COMING TO NIH STUDYING AMNIO
SITES THAT WERE LEFT OVER FROM
AMNIOCENTESIS -- --
AMNIOCENTESIS.
AND MORE RECENTLY BEEN ABLE TO
OBTAIN AND CONVERTING THEM AND
WITH THE CONTROLS.
AND THE IDEA WITH THE DATABASE.
THE INITIAL EFFORTS ARE LOOKING
AT SOME GROWTH THERE IS
SIGNIFICANT INFORMATION IN THE
BRAIN AND THE FETUS OF DOWN
SYNDROME.
AND THEN WE IDENTIFIED A THERAPY
MOVING TO THE IN VIVO MODEL.
PHENOTYPE FOR DIFFERENT MOUSE
MODELS IN DOWN SYNDROME WITH
EMBRYONIC DEVELOPMENT
DEVELOPMENT BODY GROWTH AND
BRAIN GROWTH AND DEVELOPMENT OF
THE PLACENTA AND ALSO PRENATAL
TREATMENT.
ALSO WITH THE IMPROVEMENT AS
WELL AS THE MOLECULES IN THE
PREGNANT DAMS.
I COULD TALK FOR AN HOUR ABOUT
THIS BUT I WOULD JUST GIVE YOU A
FEW SLIDES.
THE FIRST MOLECULE THE NATURALLY
I -- -- OCCURRING WHICH WAS
AVAILABLE FROM A DATABASE KNOWN
AS THE CONDUCTIVITY MAP.
OCC
OCCURS IN LEAFY GREENS AND
CITRUS. THERE ARE CLINICALS BUT
IF YOU ARE GOING TO GIVE
SOMETHING TO A PREGNANT PERSON
YOU HAVE A MUCH HIGHER BAR TO
GET OVER. IT IS A POTENT
ANTIOXIDANT AND HAS
ANTI-INFLAMMATORY EFFECTS AND
CROSSES THE BLOOD-BRAIN BARRIER
IN ANIMALS AND PROMOTES
NEUROGENESIS, SOMETHING IN
DOWN'S SYNDROME. WE HAVE DONE
STUDIES BOTH IN HUMAN CELLS AND
MICE THAT ARE PRE-PREGNANT WE
PUT THE DAM WITH THE MALE AND
FEED THEM THIS FROM TIME OF
MATING... NEXT SLIDE. SO WE HAVE
ALREADY PUBLISHED THIS ACTUALLY
DOES POSITIVE THINGS SO WE HAVE
HAD A PRINCIPAL PUBLICATION,
AMERICAN JOURNAL OF HUMAN
GENETICS. IT WILL RESCUE
OVER-EXPRESSION. I HAVE SHOWN
YOU GENES BUT THESE ARE IN THE
FOREBRAIN. THE BLACK TRIANGLE IS
THE DOWN SYNDROME MOUSE THAT HAS
BEEN -- WAS JUST FED WITH
REGULAR POWDER. THEN FOLLOWING
TREATMENT WITH APIGEN THAT SHOWS
HOW THE EXPRESSION OF THIS GENE
IS MORE AT LEVEL OF THE UPLOID
OR WILD TYPE MICE. SIMILARLY
ANTI -INFLAMMATORY PSYTOCHINES
IS PRESENT TO PREVENT INF
INFLAMMATION. WE DID A BUNCH OF
MOUSE BEHAVIORAL STUDIES THAT
SHOWED SIGNIFICANT IMPROVEMENT
IN ADULT MICE TESTED BUT SAW
INTERESTING SEX DIFFERENCE WHERE
THE RESPONSE WAS HIGHER IN MALES
THAN FEMALES. I WANT TO MENTION
BECAUSE THIS WILL GET INTO THE
OTHER PART, WE ARE VERY INTER
TES
INTERESTED IN PLACENTA. WE ARE
BLOWN AWAY BY EXPRESSION OF APP.
WE KNOW IT IS EXPRESSED IN
MULTIPLE ORGANS. BUT WITH
IMMUNOHISTO CHEMICAL EXPERIMENT,
FAIRLY RECENT THAT, IS WHY I'M
NOT SHOWING YOU A PICTURE, IT
STRIKING HOW MUCH MORE STRONGLY
EXPRESSED APP IS IN MOUSE MODELS
OF DOWN'S SYNDROME. SIMILARLY IN
THE HUMAN PLACENTA, THERE ARE
FUNDAMENTAL DIFFERENCES, THE
MAIN ONE BEING IF YOU LOOK ON
THE RIGHT WHERE IT SAYS UPLOID
THE CELLS HAVE TO FUSE. THIS
MAKES THE HORMONES CENTRAL TO
THE PREGNANCY. IF YOU LOOK AT
THAT UPLOID YOU CAN SEE THE
GREEN DOTS AND CELLULAR
MEMBRANES, THE NORMAL. IF YOU
LOOK ABOVE THIS DOES NOT FUSE IN
THE WAY IT IS SUPPOSED TO
RESULTING IN DECREASED HORMONES.
PLACENTA HAS NORMAL
ABNORMALITIES IN TRISMI21. WE
THINK IF WE UNDERSTAND FOR
EXAMPLE WHETHER PREMATURE AGING
OF PLACENTA PLAYS ROLE LONG-TERM
THIS MAY HELP US UNDERSTAND WHY
PEOPLE WITH DOWN SYNDROME AGE
PREMATURELY AND WHETHER OR NOT
THERE IS A CONNECTION WITH
ALZHEIMER'S LATER ON. THAT
BRINGS US TO CONNECTIONS BETWEEN
PLACENTA AND FETUS LONG-TERM. I
HAVE ALWAYS BEEN INTERESTED IN
KNEE NA SHORE THE DIRECTOR
ACROSS THE NIH. SHE WROTE A
PAPER AND HI POT SIS SHOWS THE
PROTEIN IMPLICATION. THERE IS
EVIDENCE THIS PLAYS MAJOR ROLES
IN BRAIN DREVELOPMENT. THE ORIGN
IS THIS MAY BE PRESENT. THERE IS
A GREAT OPPORTUNITY TO
COLLABORATE HAS INSTITUTES.
PEOPLE LAUGH WHEN I SAY AGING
BEGINS IN THE WOMB BUT IT REALLY
DOES. WE COULD, FOR SURE, CREATE
MODEL SYSTEMS TO FACILITATE
PROTEINS, NETWORK STRUCTURE AND
FUNCTION, LOOKING AT EMBRYO
GENESIS THROUGH SYNESIS AND DO
EMBRYONIC STUDIES. I WANT TO
MENTION IN THE STRATEGIC PLAN,
REFRESHED FOR THE NEXT FIVE-YEAR
CYCLE WE SINGLED OUT
NEURODEVELOPMENT TO
NEURODEGENERATION WITHES A P
ASPIRATIONAL GOAL TO ESTABLISH
LIKELIHOOD OF THESE DISORDERS
LATER IN LIFE. NEXT SLIDE,
PLEASE. I THINK IN THE INTEREST
OF TIME I'M NOT GOING TO GO OVER
THIS. WE HAVE TEN ASPIRATIONAL
GOALS. FOR OUR ADVISORY COUNCIL,
EARLIER THIS WEEK, WE HAVE BEEN
REVIEWING THOSE TEN GOALS IN
ANTICIPATION OF THE REFRESH AND
PROGRESS. WE HAVE MADE PROGRESS.
I WILL MAKE THEM AVAILABLE FOR
YOUR READING AFTER THE COUNCIL
SO YOU CAN TAKE A LOOK. FUNDING
HAS ESSENTIALLY REMAINED FLAT
WITH A LITTLE BUMP NEXT YEAR.
NEXT SLIDE. YOU CAN ALREADY TELL
I'M A BIG FAN OF THE PLACENTA,
WHICH WE JOKINGLY REFER TO AS
NICHD'S ORGAN. WE HAVE ALWAYS
BEEN CONNECTED TO A PLACENTA AT
ONE TIME. IT IS AN AMAZING ORGAN
THAT BASICALLY'S FUNCTIONS AS
YOUR HEART, YOUR LUNGS, YOUR
BRAIN, YOUR IND IN/* ENDOCRINE
SYSTEM AND PLAYS A LIFE-LONG
ROLE. PART OF OUR STUDY IS
INTERESTED IN ORIGINS OF DISEASE
AND ESPECIALLY ROLE OF HARMFUL
EXPOSURES IN UTERO AND DISEASE
LATER IN LIFE. WE HAVE
INVESTIGATED 90 MILLION IN THE
PROJECT. WHAT MAKES THAT PROJECT
UNIQUE IS IT IS LOOKING AT
DEVELOPMENT AND FUNCTION OF THE
PLACENTA BUT REALTIME AND
NONINVASIVE, SO IT IS REALLY
CREATED A NUMBER OF IMAGING
PROTOCOLS THAT ALLOW US TO LOOK
AT BLOOD FLOW, OXYGEN
DISTRIBUTION, LABELED NUTRIENT
FLOWS AND BIG EMPHASIS ON IN
NUCLEIC ACID. I MENTION DASH,
THE FUNDED DATA AND SPECIMEN
HUB. THIS IS A CENTRALIZED
RESOURCE FOR RESEARCHERS. IT IS
A GREAT OPPORTUNITY IF SOMEBODY
WANTED TO LOOK AT CERTAIN
MARKERS THAT YOU KNOW ARE
ASSOCIATED WITH
NEURODEGENERATION FOR EXAMPLE,
YOU COULD GET CORE BLOOD TODAY
OR TOMORROW IF YOU JUST REGI
REGISTERED WITH THIS RESOURCE.
IT PROVIDES A TREMENDOUS AMOUNT
OF DATA THAT'S BEEN CLEANED, NO
NEED TO GO THROUGH IRB. IT IS
WONDERFUL FOR TESTING
HYPOTHESES. IT IS USED PRETTY
HEAVILY. THERE HAVE BEEN 662
DATA REQUESTS AS OF LAST WEEK.
THERE HAVE ALREADY BEEN 106 DATA
USE PUBLICATIONS. NEXT SLIDE,
PLEASE. I WILL WANT TO
ACKNOWLEDGE ANOTHER AREA WHERE
WE ARE ALREADY PARTNERING. BUT
THERE WOULD CERTAINLY BE MORE
OPPORTUNITIES TO PARTNER. SO
THIS IS ADD HEALTH, THE
LONGITUDINAL STUDY OFSADOLESCEN
TO ADULT HEALTH. IT WAS LAUNCHED
IN GREAT 7-12. THERE HAVE BEEN
FIVE WAVES OF DATA. THE
OBJECTIVE OF WAVE FIVE WAS TO
UNDERSTAND EARLY LIFE PRECURSORS
OF CHRONIC DISEASE. WAVE SIX,
WHICH NIA IS SUPPORTING,
INCLUDES MEASURES FOR COGNITION
AND AIMS TO FACILITATE
IDENTIFICATION OF EARLY RISK
FACTORS FOR DEMENTIA. EXCUSE ME.
SO THIS IS REALLY A UNIQUE
OPPORTUNITY TO BE ABLE TO LINK
DATA FROM WHAT YOU WERE DOING IN
HIGH SCHOOL SO LIKE WERE YOU
TAKING DRUGS, FOR EXAMPLE. WHAT
DOES THAT MEAN FOR YOUR
LONG-TERM HEALTH. IT ALSO
INCLUDES INFORMATION ABOUT THE
RESPONDENT'S NEIGHBORHOODS A
COMMUNITIES AND SOCIAL FACTORS
THAT ARE SO IMPORTANT. YOU KNOW,
WE ARE VERY GRATEFUL THAT NIA
HAS ESSENTIALLY TAKEN OVER AS
THE PARTICIPANTS HAVE AGED OUT
OF OUR FOCUS GROUPS BUT WE HAVE
OTHER OPPORTUNITIES. WE ALWAYS
HAVE MANY PEOPLE REQUESTING, FOR
EXAMPLE, PREGNANCY AS A STRESS
TEST FOR LATER HEALTH. SO WE
HAVE TREMENDOUS DATA BUT DON'T
ALWAYS FOLLOW. SPEAKING OF
PREGNANCY, MENOPAUSE IS HAVING A
MOMENT. THERE IS CONGRESSIONAL
INTEREST. APPEARS IN LEGISLATION
AND MENTIONED AT NIH HEARINGS.
WE KNOW NIA FUNDS MAJORITY OF
RESEARCH MANY MENOPAUSE. WE FUND
SOME. WOULD LIKE TO FUND MORE
AND LOOK AT SOME OF THE
COMPLICATIONS IN WOMEN'S
REPRODUCTIVE BIOLOGY. WE ALSO
KNOW THERE ARE ECONOMIC AND WORK
FACTORS WITH HAVING SEVERE
SYMPTOMS IN WORKPLACE. THIS IS
THE SOCIETY FOR WOMEN'S HEALTH
RESEARCH. THAT BRINGS UP THE
RECENT PRESIDENTIAL MEMORANDUM,
THE WOMEN'S HEALTH RESEARCH
INITIATIVE. LAST NOVEMBER
PRESIDENT BIDEN ANNOUNCED THE
FIRST INITIATIVE ON WOMEN'S
HEALTH RESEARCH, LED BY FIRST
LADY DR. JILL BIDEN AND WHITE
HOUSE GENDER POLICY COUNCIL. IT
IS TO DELIVER RECOMMENDATIONS TO
AFFECT WOMEN'S RESEARCH AND HIGH
TARGET AREAS WHERE THIS COULD BE
TRANSF
TRANSFORMATIVE. THEY ARE NOT
GIVING US MONEY NOW BUT WANT OUR
IDEAS, ENGAGING THE SCIENTIFIC
AND PHILANTHROPIC COMMUNITIES.
IT IS CLEAR THE NIH HAS BEEN
ASKED TO TAKE THE LEAD ON
RECOMMENDATIONS ON RESEARCH. WE
WERE ALL ASKED TO CONTRIBUTE TO
GOVERNMENT-WIDE RECOMMENDATIONS
SUBMITTED DECEMBER 28TH.
APPARENTLY THE FIRST LADY WAS
QUITE PLEASED WITH SOME OF OUR
IDEAS. WE WANTED TO MAKE SURE
SOME OF THE CONDITIONS UNIQUE TO
PEOPLE BORN FEMALE WERE
INCLOUDED.
INCLOUDED. -- INCLUDED. THEY
WERE. IT IS UP IN THE AIR
WHETHER ANYTHING RELATED TO
PREGNANCY IS GOING TO BE
INCLUDED IN THIS INITIATIVE. WE
THINK IT IS IMPORTANT TO INCLUDE
PREGNANCY. IT IS A TIME WHEN
PEOPLE BORN FEMALE ARE IN TOUCH
WITH THE HEALTH CARE SYSTEM BUT
ALSO, AS I SAID EARLIER, A
STRESS TEST FOR LATER HEALTH.
NEXT SLIDE, PLEASE. SO IN
SUMMARY, NIA AND NICHD SHARE
MANY INTERESTS AND LIFE CORE
PERSPECTIVE. I THINK THAT REALLY
STARTED THE DAY WE WERE
AUTHORIZED AS INSTITUTES. WE'VE
HAD A FRUITFUL COLLABORATION VIA
INCLUDE AND PROGRAM OFFICIALS AT
INCLUDE HAVE BEEN A TOTAL JOY TO
WORK WITH. WE REALLY ENJOY
SUPPORTING THE ABCDS WITH YOU.
WE DO THINK THERE WILL BE FUTURE
RESEARCH OPPORTUNITIES WITH THIS
LIFETIME PERSPECTIVE ON HEALTH
AND TYPICAL AGING SUCH AS IN THE
ADD HEALTH INITIATIVE. BUT ALSO
THERE ARE OPPORTUNITIES
INCLUDING MENOPAUSE. WE ARE
INTERESTED IN CO -SUPPORTING
MENOPAUSE RESEARCH WITH YOU. I
HOPE I HAVE TWEAKED A LITTLE
INTEREST IN PLACENTA,
DEVELOPMENTAL ORGANS OF HEALTH
AND DISEASE. THEN OPPORTUNITIES
TO DETERMINE IF EARLY
INTERVENTIONS, EITHER IF THEY
OCCUR PRE-NATALLY OR EARLY
CHILDHOOD AFFECT LONG-TERM
HEALTH. SO I THINK THAT IS IT. I
HAVE LEFT TIME. I KNOW WE
STARTED LATE. I HAVE LEFT TIME
FOR QUESTIONS. I ASSUME WE HAVE
TEN MINUTES FOR QUESTIONS, SO
THANK YOU FOR YOUR ATTENTION.
>> DIANE, THANK YOU SO MUCH.
SO MANY AREAS FOR QUESTIONS. I
GET TO TALK TO YOU MORE
FREQUENTLY THAN COUNCIL MEMBERS.
LET ME START BY GIVING PRIORITY
TO QUESTIONS COUNCIL MEMBERS MAY
HAVE. IF THERE IS TIME. FRANK.
>> THANK YOU FOR THE GREAT
TALK. SO MANY GREAT LESSONS. I'M
CURIOUS ABOUT THIS OVERLAP OF
AIMING. DOWN'S SEEMS LIKE SUCH A
POWERFUL PROTOTYPE BUT HAS THIS
COME UP IN A LOT OF THER E OTHE
AREAS? I HAVE A SISTER WITH
CEREBRAL PALSY, STATIC MOTOR...
IF YOU LOOK UP THAT DISEASE, 99%
WILL BE PEDIATRIC-BASED. HOW
THESE PEOPLE DEAL WITH AGING,
HOW AGING AFFECTS IT. WHETHER
THERE IS ACCELERATED AGING OR
NOT. SO IF I WERE TO APPLY FOR A
GRANT TO INVESTIGATE AGING IN
CEREBRAL PALSY, WHAT WOULD
HAPPEN? WOULD I FALL THROUGH THE
CRACKS? WHO WOULD I GO TO? HAS
THIS PLATFORM BEEN SET UP TO
DEAL WITH THIS OVERLAP?
>> YAH, SO OFF THE TOP OF MY
HEAD, I'M NOT AWARE OF SOMETHING
SPECIFICALLY LOOKING AT AGING IN
CEREBRAL PALSY; THEREFORE IT IS
A GAP. I THINK THE LOGICAL PLACE
TO GO WOULD BE NATIONAL CENTER
FOR MEDICAL REHABILITATION
RESEARCH. THEY FUND THE MAJORITY
OF RESEARCH ON CEREBRAL PALSY. I
THINK SOME IS ALSO AT NINDS. I
THINK AGAIN IT IS THIS NATURAL
HISTORY -- AGAIN, I'M NOT AN
EXPERT IN THIS AREA BUT I THINK
IT COULD VERY WELL BE A GAP
AREA.
>> YAH, I DON'T WANT TO
HIGHLIGHT THAT GIVEN DISORDER
BUT AS AN EXAMPLE OF THINGS WE
CONSIDER CHILDHOOD OR PEDIATRIC
DISORDERS PROBABLY HAVE
BIOLOGICALLY CRITICAL COMPONENTS
OF AGING-RELATED MECHANISMS, SO
I THINK YOU ARE REMINDING ME, AT
LEAST, OF THAT. HOW IMPORTANT
THIS IS. I GUESS IT IS A KEY
ROLE FOR NIA TO DEAL WITH THESE
AGING ASPECTS ACROSS THE WHOLE
SPECTRUM. IT IS FUNNY TO SAY
THAT, DEAL WITH AGING ACROSS THE
ENTIRE LIFE SPAN, RIGHT?
>> BUT MY POINT IS THAT THERE
MAY BE CLUES EARLIER IN LIFE
THAT EITHER IDENTIFY PEOPLE AT
RISK OR MIGHT GIVE US NEW
KNOWLEDGE ABOUT INNOVATIVE
THERAPIES, SO THAT IS WHY IT IS
AN OPPORTUNITY FOR PARTNERSHIP.
>> THANK YOU.
>> WE CERTAINLY RECOGNIZE,
APPRECIATE WORKING WITH NICHD.
THERE HAVE BEEN A NUMBER OF
INITIATIVES LOOKING AT IMPACTS
OF EARLY LIFE EVENTS ON LATER
CONSEQUENCES, BE THEY
ENVIRONMENTAL, EARLY OR GENETIC
DETERMINATIVE EVENTS, AND WILL
CONTINUE. SHARING INFORMATION
WITH ALL OF YOU IS PART OF THE
LEARNING PROCESS. I THINK SANJAY
WAS NEXT.
>> YAH, THANK YOU. THANK YOU
FOR THE OUTSTANDING
PRESENTATIONS. ONE OF THE AREAS
NIA IS INVESTING HEAVY IS THE
SOCIOLOGICAL BASIS OF THESE
DISEASES. WONDER WE KNOW THEY
ARE ACTIVE THROUGHOUT THE LIFE,
PERHAPS IN UTERO. WONDER IF
THERE IS RESEARCH AS RELATES TO
DOWN'S SYNDROME AND OTHER
RELATED DISORDERS.
>> SO THANKS FOR THAT
QUESTION. SOCIAL DETERMINANTS OF
HEALTH ARE DEFINITELY AN
INCREASING PART OF OUR EMPHASIS.
THERE IS NO QUESTION THAT IT
AFFECTS FETAL DEVELOPMENT AND
ALSO THE SUCCESS OF THE
PREGNA
PREGNANCY AND MATERNAL HEALTH
LONG-TERM. I WOULD SAY MOST OF
THE FOCUS HAS BEEN ON HOW THE
SOCIAL DETERMINANTS OF HEALTH
AFFECT CHILD DEVELOPMENT. WE
HAVE A BIG CHILDHOOD DEVELOPMENT
AND BEHAVIOR BRANCH WHICH TAKES
MOST UP THROUGH ADOLESCENCE BUT
AGAIN THEY HAVE TO HAND OVER TO
AN ADULT-ORIENTED INVESTIGATOR.
I THINK THERE WOULD BE
OPPORTUNITIES TO SHARE THAT DATA
OR EX CHANGE DATA. WE ARE
COLLECTING IT.
>> KAREN.
>> THANK YOU, DR. BIANCHI FOR
THE TALK. IT WAS LOEL. AS A
PROFESSOR OF PEDIATRICS IT
HELPED JUSTIFY MY ROLE ON BEING
HERE. MY QUESTION RELATES TO
YOUR DOWN'S SYNDROME MODEL
WITHIN YOUR MOUSE STRAIN. I
GUESS I'M SOMEWHAT UNFAMILIAR
WITH THAT. WE WORKED WITH A
PRODROY STRAIN OF ANIMALS. IT
WAS AN ANTIPLOID, BUT NOT
STABLE. ALL TYPES THAT WERE
PREDISPOSING TO SYNDROMES LIKE
DOWN'S WOULD BE. I'M CURIOUS,
THE MODEL YOU ARE USING AND
WITHIN YOUR DATA SETS, DOWN'S
SYNDROME IS REPRESENTED BY THE
TRISOME21 BUT ARE YOU HAVING ANY
OTHER ANTIPLOMES WITH A PRAGERIA
TYPE EFFECT?
>> NO, BUT THANK YOU FOR THE
QUESTION. WE HAVE OUR HANDS FULL
WITH THE FOUR MOUSE. HUMAN
CHROMOSOME 21 DOES NOT HAVE AN
EXACT EQUIVALENT IN MOUSE. IT IS
PART OF MULTIPLE CHROMOSOMES,
MAYBE MOUSE 16. TRISOMY OF MOUSE
CHROMOSOME 16 IS LETHAL SO
VARIOUS MODELS HAVE BEEN MADE
THAT INCORPORATE MOUSE
CHROMOSOME 17 AND 10. BUT I WILL
TELL YOU THAT I AM IN THE SAME
-- MY I INTRAMURAL LAB IS IN THE
SAME CENTER AS DR. FRANCIS'S
LAB. HE'S BEEN STUDYING PROGERIA
AND VARIOUS THERAPIES. WE ARE
INTERESTED IN MPLACENTAS OF MIC
AND THEIR MODELS, WHICH I THINK
THEY DEVELOPED IN THEIR VERSION
OF PROGERIA. IT IS SOMETHING WE
WOULD LIKE TO LOOK AT BECAUSE
THEY BASICALLY DON'T USE THE
PLACENTA. I'D BE CURIOUS TO KNOW
IS APPP HIGHLY OVER-EXPRESSED IN
PLACENTAS OF THOSE MICE.
>> ONE LAST CONCEPTUAL THING
TO CLOSE. IN SPACE OF PEDIATRIC
AND ADOLESCENT MEDICINE I THINK
A LOT OF PATHOLOGIES OR
HALLMARKS OF AGING WERE IGNORED
A LONG PERIOD OF TIME. IT WASN'T
THAT WE WERE LOOKING, ASSUMING
IT WAS SOMETHING OLD PEOPLE GOT.
BUT THE INVIGORATING OF AGING
FIELD, LOOKING NOW DO WE SEE
EVIDENCE OF SIN NESENSE IN YOUNG
INDIVIDUALS AMPLIFIED AS WELL,
WONDERFUL TALK.
>> THANK YOU.
>> HI. DR. BIANCHI, I WORK
WITH CHEROKEE NATION IN
NORTHEAST OKLAHOMA. WITH A LOT
OF NATIVE AMERICAN POPULATION.
MY QUESTION HAS NOT SO MUCH
AGING BUT AUTISM DISORDER WHICH
FALLS WITHIN YOUR PORTFOLIO.
WONDERING WHAT KIND OF EFFORTS
ARE BEING MEAT MADE N /* /* --
MADE IN INDIAN COUNTRY. I HAVE
AN INTEREST IN THIS AREA.
>> YOU AND OUR NEW NIH
DIRECTOR, NOT SURE IF YOU KNEW
DR. MONICA, THE NEW DIRECTOR OF
NIH, HAS AN ADULT SON WITH
AUTISM.
>> HE JUST TURNED 30.
>> OH, HAPPY BIRTHDAY. HER
SON IS 27. THE INTERAGENCY
CONSORTIUM ON AUTISM RESEARCH IS
MEETING TODAY, SO I HEARD HER
SPEAKING ABOUT HER SON, BEN. WE
JOINTLY FUND THE AUTISM EXCEPT
CENTERS OF EXCELLENCE, A. C. E.,
WITH NATIONAL INSTITUTES OF
HEALTH. OFF THE TOP OF MY HEAD I
CAN'T TELL YOU EXACTLY WHAT WE
ARE FUNDING IN INDIAN COUNTRY,
BUT IF YOU SEND ME AN EMAIL,LY
BE ABLE TO ANSWER YOU.
>> ABSOLUTELY.
>> YEAH.
>> I NOTICE THERE IS WORK
DONE WITH NAVAJO NATION. I'M NOT
FAMILY WITH ANYTHING IN FOUR,
FIVE OF BIGGEST TRIBES IN
OKLAHOMA. I CAN REACH OUT TO
YOUR LATER.
>> YEAH.
>> I WORK WITH THIS
COMMUNITY, I LIVE THERE. I KNOW
THERE ARE HARDLY ANY SERVICES.
WE JUST HEAR ABOUT PEOPLE AS A
CHILD AND CONCERNS ME.
>> I WANT TO T BE SPECIFIC TO
LET YOU KNOW EXACTLY --
>> EVEN IF NOTHING'S BEEN
DONE -- I'M SURE THERE'S A LOT.
BUT WE CAN FIND WAYS TO WORK
TOGETHER TO BRING MORE RESEARCH
TO INDIAN COUNTRY. THAT IS THE
POINT I'M TRYING TO MAKE.
>> THANK YOU.
>> THANK YOU FOR YOUR
RECOMMENDATION.
>> CERTAINLY IN MATERNAL
HEALTH, YOU KNOW, WE ARE VERY
CONCERNED ABOUT INCREASED RISK
OF MATERNAL MORTALITY IN VARIOUS
TRIBAL NATIONS. WE ARE WORKING
ON THAT AS WELL.
>> THANK YOU SO MUCH.
>> MIRTA.
>> HI, DR. BIANCHI, THANK
YOU. THIS WAS AMAZING. I'M A
NON-SCIENTIST AND SIT ON THE
COUNCIL AND THE DIANE CONSORTIUM
NETWORK. PRIMARILY REPRESENTING
FAMILIES, ADAD FAMILIES. SO
MULTIPLE MEMBERS OF MY FAMILY
AND ALSO I HAVE BEEN A
CAREGIVER. I AM ABSOLUTELY JUST
AMAZED AT EVERYTHING YOU
PRESENTED. I THANK YOU FOR THAT
WORK. ESPECIALLY LOOKING AT --
I'M IN SPECIAL EDUCATION,
DIRECTOR CURRENTLY OF SPECIAL
EDUCATION BUT I HAVE BEEN IN THE
FIELD SINCE I WAS 19 YEARS OLD.
SO SEE THE WORK DONE WITH DOWN'S
SYNDROME AND LOOKING AT ADAD, IT
IS A WONDERFUL THING TO SEE IT
IS HAPPENING. I HOPE A LOT MORE
WILL BE -- WE WILL LEARN MORE
FROM THAT. I ALSO WANTED TO --
TO ME YOU SAID SOMETHING AROUND
-- YOU SAID MIGHT BE CRAZY BUT I
WILL TELL YOU WHAT, CRAZY IS
REALLY, REALLY GOOD. I AM SO
EXCITED TO SEE ALL THE WORK THAT
YOU'RE DOING WITH THE PLACENTA.
TO ME THAT ALL MAKES ABSOLUTE
SENSE. AGAIN, I'M NOT A
SCIENTIST BUT REALLY MAKES
SENSE. I HOPE MORE PEOPLE WILL
BE INTERESTED IN STUDYING THAT.
THANK YOU FOR YOUR PRESENTATION
AND ALL YOUR WORK.
>> THANK YOU, MARITZA FOR
YOUR COMMENTS, APPRECIATE IT.
>> THANKS. ONE MORE QUESTION.
>> THANK YOU FOR THE VERY
EXCITING TALK. ESPECIALLY
EXCITING ABOUT YOUR BIG COHORT
ON THIS DOWN'S SYNDROME. ALSO
ESPECIALLY ALZHEIMER'S BUT ITS
ROLE AND AFFECT ON EARLY ON
DESTINY SET OF THIS IS NOT WELL
STUDIED. BECAUSE OF THE SMALL
COHORT. WONDER WHETHER YOU HAVE
ANY INFORMATION ABOUT THE
DEGENERATIVE EFFECT IN THE BIG
DOWN'S SYNDROME COHORT.
>> THAT WOULD BE SOMETHING,
YOU COULD ASK THE QUESTIONS OF
THE DATA RESOURCE. YOU KNOW, I
PERSONALLY HAVING PLUMBED IT FOR
THAT PARTICULAR TYPE OF
QUESTION.
>> THAT WOULD BE GREAT. I
WILL CONTACT TO SEE IF I CAN DO
SOMETHING THERE.
>> YES.
>> THANK YOU.
>> ALL RIGHT. THANK YOU VERY
MUCH. DR. BIANCHI, AMAZING TALK.
THANK YOU FOR ANSWERING ALL THE
QUESTIONS FROM ALL OUR COUNCIL
MEMBERS. IT WAS INSPIRATIONAL
AND INFORMATIVE OF HOW MUCH
OVERLAP BETWEEN OUR INSTITUTES
AND WHAT MANY POSSIBILITIES FOR
FURTHER INTERACTIONS AND NEW
ARENAS FOR RESEARCH IN THAT
HORIZON.
>> GREAT.
>> THANKS, DIANA. WE CAN
FOLLOW UP TOMORROW MORNING.
>> WONDERFUL. THANK YOU FOR
INVITING ME. I WILL TRY TO
ANSWER SOME OF THE QUESTIONS IN
THE CHAT BOX TOO.
>> THANK YOU AGAIN.
>> THANK YOU.
>> ALL RIGHT. SO NEXT UP WE
HAVE ONE MORE SPEAKER, THEN WE
WILL BE HEARING FROM OUR
INTRAMURAL PROGRAM SO TURN OVER
TO OUR DIRECTOR OF DIVISION OF
NEUROSCIENCE TO INTRODUCE THE
NEXT SPEAKER.
>> THANK YOU. I'M REALLY
PLEASED TO INTRODUCE DR. RYAN,
THE SPEAKER FOR THE HIGHLIGHT
TODAY. HE IS A PROFESSOR AT THE
UNIVERSITY NORTH TEXAS IN FORTH
WORTH AND PRINCIPLE INVESTIGATOR
OF HEALTH AND BRAIN STUDY,
HEALTH DISPARITIES. WE WILL HEAR
ABOUT THAT TODAY. AS YOU KNOW,
THIS IS A VERY IMPORTANT, HIGHLY
COMPREHENSIVE STUDY OF
ALZHEIMER'S AMONG THREE LARGEST
RACIAL ETHNIC GROUPS IN THE U.S.
CONNECTED INCLUDING
AFRICAN-AMERICAN, HISPANIC,
NON-HISPANIC WHITES. WE WILL
HEAR A LOT MORE ABOUT THESE VERY
EXCITING PROJECT. BUT THE
PROJECT HAS MAIN FOCUS
UNDERSTANDING COURSE FACTORS
INCLUDING BIOLOGICAL,
ENVIRONMENTAL, BEHAVIORAL, HOW
THEY IMPACT ALZHEIMER'S DISEASE
IN LATE LIFE. DR. RYAN IS ALSO A
GLOBAL EXPERT ON THE USE OF
BLOOD-BASED BIO MARK ERS FOR
GENERATION OF PRECISION MEDICINE
APPROACHES AND STRATEGIES FOR
AD, PARKINSON'S, LOUIE BODY AND
PARKINSON'S. WITHOUT FURTHER
ADIEU, DO THE HONORS. THANK YOU
FOR ACCEPTING INVITATION.
>> THANK YOU. IT IS A
PLEASURE TO BE HERE AND REALLY
NICE TO SEE SO MANY FRIENDS ON
THIS ZOOM. BEFORE I DON'T WANT
TO FOR GET SINCE THE DETECTOR
SPEAK ABOUT ABCDS, IS DR. UDON,
THE DATA, APO4 IS THERE. THERE
ARE INVESTIGATORS AND I'M HAPPY
TO CONNECT YOU CAN SOME PEOPLE.
I ACTUALLY AM THE DIRECTOR OF
THE MIX 4 AND 3 OF THIS. ONE OF
THE NICE THINGS IS THE OMIX OF
THESE ARE OVERLAPPED. BECAUSE WE
ARE 30 AND ABOVE, HABSHD NOT
ONLY FROM MULTI -ETHNIC BUT
YOUNGER SIDE WE HAVE BUILT-IN
CROSS COLLABORATION CAPACITY
FROM A NOMICS ASPECTS AND COVER
IMAGING WORK. SO JUST BEFORE I
FORGET -- WELL I LOVE THE STUDY
AND HAVE BEEN INVOLVED WITH IT
SINCE THE INCEPTION. I WILL TALK
ABOUT HABSHD. IT IS NOT JUST
WHAT WE HAVE DONE. WHAT CERISE
AND DEMALI HAVE ASKED HOW WE
COVER, HOW WE HAVE DONE IT. THE
STRUCTURE IS APPARENTLY A BIT
DIFFERENT FROM WHAT SOME OTHER
RESEARCH GROUPS AND STRUCTURES
ARE PULLED TOGETHER AND
FUNCTION. NEXT SLIDE SO BRIEFLY
IN TERMS OF STRUCTURE, THIS IS
SIMILAR TO ANY LARGE-SCALE
PROGRAM WHERE WE HAVE AN
ADMINISTER CORE WHERE I RUN THE
MPI TEAM AND HELPS WITH THE
ADMINISTER COURSE AND IMAGING
CORE IS RUN BY DR. CORE AND
BRADLY AND LEAD WITH JOHNSON AND
MAPSTONE. THE OUTREACH, DR.
JOHNSON, MILKY AND HILL, RAMON
AND PALMER. THE DEVELOPMENT LIKE
OQUONKO AND DR. VERMIT AND THREE
PROJECTS. NEXT SLIDE, PLEASE. SO
THIS SLIDE REALLY, TO ME,
ENCOMPASSES THE NATURE OF THIS
ENTIRE PROGRAM. AS YOU ALL KNOW,
U19s ARE ONE LARGE PROGRAM. NOT
THREE SEPARATE PROJECTS LIKE A
PBG. PROJECT ONE IS DESIGNED TO
LOOK AT AM LLOYD TOWEL AND
BIO MARKERS. NOT JUST TO LOOK AT
BRAIN IMAGING, HOWEVER. WE ARE
DOING AMALOYID BUT ALSO ET
CETERA. THE WAY WE ARE LOOKING
IS VERY MULTI FACTORIAL AND
STRUCTURAL MODELLING TO BUILD
CON TRUKT OF AMYLOID BROADER
THAN CSF OR BRAIN. WE HAVE
LAUNCHED THE LUMBER PUNCTURE
STUDY SO WE HAVE STARTED IN THAT
PROGRAM. PROJECT TWO, PART WE
PROPOSE AN ATMV VASCULAR,
METABOLIC AND INFLAME TOIR. SO
WE ARE LOOKING AT THOSE FACTORS.
HOW DO THEY RELATE TO AND IMPACT
THE AMALOID REGENERATION IN
RECIPROCAL MATTER AND EARLY ON?
OUR HYPOTHESIS ISN'T THAT IT IS
THE PRESENCE BUT WHEN THEY
DEVELOP AND HOW THEY DEVELOP
OVER TIME. WE HAVE DATA COMING
OUT SHOWING THE DIFFERENT SUB
TYPES OF TOW BASED ON THE PET
SCANS. THESE SUB TYPES OF TOW
VERY AND CO MORBIDITIES IMPACT
THESE THINGS. WE NOW HAVE VERY
CLEAR DATA SAYING THE FRAMEWORK
VARIES SIGNIFICANTLY BETWEEN
GROUPS AND THAT VASCULAR
METABOLIC AND INFLAMMATORY
FACTORS HAVE AN IMPACT ON THESE
MAR
MARKERS. IN THE MIDDLE I DON'T
BELIEVE YOU CAN STUDY THE
ABSENCE IN SOCIAL OWE CULTURAL.
DOING SO IS BLINDERS AND MISSING
IMPORTANT COMPONENTS. EVERYTHING
WE DO IS WITHIN A SOCIOCULTURAL
CONTRACT. SO WITHIN THE
MULTI AND FULL-SCALE WE ARE
CAPTURING DATA AROUND THESE
BEHAVIORAL FACTORS. MANY KNOW
ABOUT AREA DEPRIVATION INDEX. WE
ARE CAPTURING THAT NOT ONLY
WHERE CURRENT BUT ACROSS ENTIRE
LIFE SPAN IN UNITED STATES AND
MEXICO, SO WE CAN LOOK AT CHANGE
OVER TIME. IN MEXICO THERE IS
INDEX OF MARGINIALIZATION. WE
ARE CAPTURING PERCEIVED RACISM.
DO YOU HAVE INSURANCE. BROAD
VARIETY OF COMPONENTS. NEXT
SLIDE, PLEASE.
SO ONE OF THE QUESTIONS THAT
I GET IS YOU ARE IN TEXAS. WHY
IS WHERE YOU ARE A GOOD PLACE TO
DO THIS SORT OF WORK? WELL,
FIRST AND FOREMOST I HAVE BEEN
DOING HEALTH DISPARITIES
RESEARCH OVER TWO DECADES SO
THIS IS WHAT I HAVE BEEN DOING
FOR MY ENTIRE CAREER LONG BEFORE
BLOOD-BASE BIOMARK ERS. IT'S
ALWAYS BEEN A FOCUSED RESEARCH
SO WE CONTINUE TO GROW OVER
TIME. WHY DFW? DALLAS/FORT WORTH
IS 7TH LARGEST METROPOLITAN AREA
IN UNITED STATES WITH AROUND 8
MILLION, SOON TO BE 9 MILLION.
WHERE THE UNITED STATES WILL BE
BY 2040, 2045 IN TERMS OF RACE
AND ETHNICITY, WE ALREADY ARE.
THIS IS WHY WE MOVED HERE IN THE
FIRST PLACE. DALLAS/FORT WORTH
IS A MICROCOSM WHERE THE UNITED
STATES WILL BE IN THE NEXT
SEVERAL DECADES WITH REGARD TO
RACE AND ETHNICITY. IT IS AN
IDEAL LOCATION TO CONDUCT THIS
SORT OF WORK. NEXT SLIDE,
PLEASE. SO WHERE ARE WE? ONE OF
THE THINGS THAT WE HAVE DONE
WITH DEMALI AND CERISE IS WE
ALWAYS TRY TO PROVIDE REGULAR
UPDATES TO OUR PROGRESS. ONE OF
THE THINGS BECAUSE OF THE M
ISES, WE ARE ALMOST NEVER BEHIND
SCHEDULE. WE ARE ALMOST ALWAYS
AHEAD OF SCHEDULE. FOR EXAMPLE,
ONE QUARTER THROUGH THE YEAR,
OUR MILESTONE FOR THE YEAR IS
1400 PARTICIPANTS. US AS A GROUP
WE SET OUR MILESTONE AND GOALS.
THE MILESTONE IS WHAT WE MUST
HIT AND GOAL IS WHERE WE WANT.
THE MILESTONE IN OUR NOA IS
1,400 PARTICIPANTS. THAT IS
TIMES FOUR OR FIVE VISITS SO WE
DO BETWEEN 5,000 AND 10,000
RESEARCH VISITS A YEAR. AT 20%
OF YEAR WE ARE ALREADY AT 30% OF
OVER MILESTONE WITH REGARD TO
PARTICIPANT RECRUITMENT AND ON
TARGET FOR OUR GOAL. BASED ON
WHERE WE ARE NOW WE ANTICIPATE
BEING 1600-PLUS PARTICIPANTS. IN
THAT MANNER WE ARE ALSO -- OUR
MILESTONE FOR PET SCANS IS ONE
EXPLICITLY LISTED. AS SUCH WE
ARE AHEAD OF SCHEDULE THERE. ON
RIGHT WHAT I HAVE TRIED TO
PROVIDE IS A BRIEF SNAPSHOT.
WHERE ARE WE? WHAT IS THIS DATA?
WHAT IS GOING ON, HOW IS THIS
HELPING? SO IN THE U19 WE HAVE
NOW IN A LITTLE OVER A YEAR WE
HAVE SEEN 2,142. SINCE INCEPTION
OVER 4,000. ALL DATA IS PUBLICLY
AVAILABLE. WE HAVE NOW CONNECTED
OVER 3,500AMYLOID PET SCANS,
BROKEN DOWN BETWEEN RACE AND
ETHNICITY. SOMETHING QUITE
HONESTLY IS WHAT WE WERE TOLD WE
COULDN'T DO. WE WERE TOLD YOU
CAN'T RECRUIT BLACKS AND
HISPANICS, THEN CAN'T DO MRIs OR
PETS. IN FACT, WE HAVE HAD HIGH
SUCCESS RATES. OVER 2100 PET TOW
SCANS. THIS IS THE LARGEST
COLLECTION OF AMAYLOID AND TOW
SCANS IN HISTORY AND ALL
PUBLICLY AVAILABLE. WE ARE
SUPPOSED TO DEPOSIT WHOLE
SEQUENCING IN 23 AND BEFORE THE
END OF 24 AND ANTICIPATE ANOTHER
1500 IN DATABASE AND DEPOSITING
GIWAS, ANCESTRY AND ONE THE
METHY LATION. SO INCREASING THE
THIS AND BASH IS SPEAKING TO
INCREASE AWARENESS OF WHAT WE
ARE DOING SO PEOPLE KNOW WHAT IS
THERE, WHAT IS AVAILABLE BECAUSE
ALL THIS DATA CAN THEN BE -- THE
PHENOTICAL DATA FOR STUDIES. IN
THE LAST 18 MONTHS WE PROVIDE
OVER 300 DATABASES AND LINKED TO
ABCS AND CLEAR AD, RECENTLY
FUNDED, I SERVE AS CHAIR OF
THEIR ADVISORY COMMITTEE SO
MAKING THE DATA AVAILABLE. WE
COLLABORATED WITH ADBYCAP,
NUMEROUS OTHER PROJECTS. THE
REPOSITORY IS ENORMOUS. CLOSE TO
5,000ALOQUATS. WE DO BUFF FI
CODE, SERUM, PLASMA. WE HAVE A
GOP1 TUBE SPECIFICALLY FOR
GOP1GLUCOGON AND INSULIN. WE ARE
ADDING PATCH GENE TUBES SO WILL
BE HAVING THAT AVAILABLE AS WELL
BECAUSE WE ARE STARTING
TRANSCRIPT. NEXT SLIDE, PLEASE.
SO HOW -- ONE OF THE QUESTIONS
WE GET OFTENTIMES IS HOW IS THIS
POSSIBLE? ALL PARTICIPANTS ARE
IN A SINGLE SITE. THAT IS WHAT I
DIDN'T MENTION. THERE ARE AROUND
17 SITES AFFILIATED WITH THE
STUDY BUT ALL PARTICIPANTS HELP
IN PLACE. SO THIS ENTIRE
INFRASTRUCTURE WAS BUILT OVER
TIME SPECIFICALLY TO MEET THIS
STUDIES NEEDS FOR SCALABILITY.
SO, FOR EXAMPLE, RIGHT NOW THE
FLOOR I'M ON WITH MY OFFICE IS A
20,000 SQUARE FOOT CLINICAL
FLOOR IN THE CLINICAL BUILDING.
THE REASON IS THE COMMUNITY CAN
DRIVE UP AS THOUGH THEY ARE
SEEING THEIR DOCS. IT IS EASY
YER TO GET TO, OVERHANG. WE ARE
IN THE PROCESS OF CAPTURING
ANOTHER 10,000 SQUARE FOOT RIGHT
ABOVE WHERE I'M AT NOW. WE HAVE
ALSO BUILT OUR OWN CUSTOM
SYSTEM, ALL THE WAY FROM
GROUND-UP BECAUSE AT TIME WHEN
WE STARTED THERE WAS NOTHING
COMPREHENSIVE ENOUGH FOR OUR
NEEDS. SO WE HAVE A CUSTOM
SCHEDULING SYSTEM, ELECTRONIC
DATABASE SYSTEM, LYMPH SYSTEM
THAT ARE 100% INTERCONNECTED.
FOR EXAMPLE WHEN SOMEONE SHOWS
UP, CHECKS IN AT THE FRONT DESK,
WHEN WE CHECK BAG WITH BLOOD
TUBES BEFORE PHLEBOTOMY, THEY
ARE NOT ONLY IN NEC FOR THE
ASSISTANT BUT IN THE LIMBS FOR
LABS EXPECTING BLOODS TO COME
OVER FOR PROCESSING. WE HAVE A
FULLY DEDICATED IMAGING CENTER.
THIS IS SOMETHING THAT WAS
REQUIRED. THERE IS NO WAY WE
COULD HAVE POSSIBLY DONE THIS IN
THE ABSENCE SO WE HAVE A FULLY
DEDICATED TO STATE-OF-THE-ART 3T
MRI, SIEMENS AND P2 SO NEVER A
BILLABLE PATIENT SCENE. IT IS
100% RESEARCH DEDICATED. WE CAN
DO OVER -- CLOSE TO CAPACITY OF
5,000 PER YEAR PET SCANS AND
5,000MRIs. ONE WENT OVER TO
OVERLAP THERE BUT NO OTHER
COMPANY WAS WILLING TO PROVIDE
TRACE ERS. THEY ALL TOLD US NO,
GE AND EVERYONE TOLD US NO
BECAUSE OF THE THROUGH-PUT
CAPACITY AND WE WERE SEEING
ANYWHERE BETWEEN 100 TO
150AMYLOIDS AND 50 TOW. WORKING
WITH SEW FI WE WERE ABLE TO MAKE
IT WORK. NOW RUN AROUND 200 PET
SCANS A MONTH, ON AVERAGE. IN
TERMS OF THEO MIX, THE REASON
KEEP UP IS UPDATED. IT IS NOT BY
HAND. WE HAVE HAMILTON EASY
BLOOD THAT PROCESS ALAQUOT INTO
EXACT NUMBERS. IF WE SAY THERE
ARE 250 MICRO LITERS THERE
ACTUALLY IS. NEXT SLIDE. THISS
IN MY OPINION, PROBABLY THE
SECRET TO OUR SUCCESS. MANY MY
EXPERIENCE GREAT SCIENTISTS
DON'T NECESSARILY MAKE GREAT
MANAGERS. WE HAVE BUILT THE TEAM
STRUCTURE IN A MANNER THAT, ONE,
IS VERY TRANSPARENT. WE HAVE
WEEKLY OR BIWEEKLY MEETINGS,
MONTHLY FOR SOME. EVERYTHING WE
HAVE DONE WAS BUILT FOR
SCALABILITY WHY IS WHY WE
BROUGHT OUR OWN EDC. RED CAP
COULDN'T MEET OUR CAPACITY BUT
WOULDN'T INTEGRATE WITH THE
OTHER SYSTEMS. WE ALSO -- I GET
A WEEKLY REPORT. I KNOW WHERE
EVERYTHING IS, HOW MANY PHONE
CALLS ARE DONE EVERY WEEK OR
PARTICIPANTS ARE SEEN EVERY
WEEK. NOT FOR MICROMANAGEMENT
BUT SO WE CAN SHARE THE
INFORMATION, HAVE RAPID
COMMUNICATION AND MONITORING
WHICH ALLOWS FOR ADAPTABILITY
AND FLEXIBILITY. WE WILL BUILD
IN NOT-SEEN PARTICIPANTS SO WHEN
WE HAVE TO DO -- SOMEONE BROUGHT
TO ONE OF OUR MEETINGS DR. RYAN
DON'T THINK YOU'D WANT TO HEAR
THIS BUT WE CAN'T SEE
PARTICIPANTS ON SO SO OF A WEEK.
THIS WAS THE SCHEDULING PERSON.
MY FIRST RESPONSE WAS WE NEVER
SHOOT THE MESSAGE. THERE IS NO
BAD NEW JUST NEWS. IT WOULD TURN
AIRPORT WONDERFUL THING. WE HAD
A BACK LAUGHING OF NEEDING TO DO
INFORMANT INTERVIEWS. WE DIDN'T
SEE PARTICIPANTS FOR A WEEK AND
WERE ABLE TO THE GET CAUGHT UP.
THIS ALLOWS FOR QUALITY CONTROL
AT LEVEL THAT IS DIFFERENT
OTHERWISE .
THE LAST PIECE THAT IS M COME
/* COMING IS FOUR PASS. ONE OF
THE THINGS AT THE ARE REQUESTS
AND MEETING WITH OTHER TEAMS ON
HOW. THERE'S TWO PROGRAMS
LOOKING AT INCREASING DIVERSITY.
I'M ENTERING THEM ON NOT ONLY
HOW DO YOU RECRUIT DIVERSE
POPULATIONS WITH COMMUNITIES OF
COLOR BUT BUILD THE SYSTEM,
TRACK IT, MONITOR IT SO YOU KNOW
WHERE TO MAKE CHANGES. NEXT
SLIDE, PLEASE. THIS IS WHAT I
MEANT WHEN I SAID I THINK IT IS
IMPORTANT TO HAVE THE RIGHT
PEOPLE AT THE TABLE. IN MY
EXPERIENCE WORKING WITH GROUPS
FROM ALL OVER, I WOULD GO TO
ADMINI ED
A ADMINISTER SCORE MEETING. WE
NEEDED OPERATIONS IN THOSE
MEETINGS SO BUILT THE SYSTEM IN
SUCH A MANNER THAT FOR EXAMPLE
I'M THE LEAD BUT WE GAVE
DIRECTOR TITLES TO STAFF. EVEN
THOUGH I'M IN MEETINGS, SHE RUNS
THE MEETINGS. IN THE MEETINGS
THE IMAGING CENTER IS
REPRESENTED. CLINICAL CORE,
OUTREACH IS THERE SO IF CHANGE
NEEDS TO HAPPEN WE HAVE
LEADERSHIP ACROSS GROUP S SO
WHEN WE SAY WE WILL GO FROM
SCHEDULING 65 TO 72 THE IMAGING
CENTER, NO, THIS IS WHAT WE NEED
TO DO TO KEEP UP. WE GOT MORE
BLOOD SAMPLES COMING IN.
EVERYONE CAN MONITOR AND
PRO INPRO
PROVIDE FEEDBACK AS TO WHEN TO
IMPLEMENT CHANGES. THIS ALLOWS
TEAM TO TAKE HOLD OF THE STUDY
ITSELF. NEXT SLIDE, PLEASE. THIS
IS WHAT I MEANT WITH FOREC
FORECASTING. WE HAVE TRACKED
DATA ON HOW MANY WE SCHEDULE PER
WEEK. SO THIS WOULD BE MONTHLY.
WE KNOW WHEN WE ARE CHANGING THE
NUMBER OF PEOPLE SCHEDULED BUT
FOR THE LAST SEVERAL YEARS KNOW
OUR SHOW-UP RATES BY MONTH. WE
KNOW IN JANUARY WE NORMALLY HAVE
A 65% SHOW-UP WITH 35% NO-SHOW
RATE. SOME OF THESE NUMBERS ,
THE JULY IS THE JANUARY BECAUSE
DECEMBER AND JANUARY PEOPLE
DON'T WANT TO SHOW UP, THEY
DON'T WANT TO DO HOLIDAYS. WHAT
WE CAN DO WITH THIS AND THEN
DOING NOW IS SAY OKAY NOT ONLY
DO WE KNOW WHERE WE WILL BE AT
THE END OF YEAR 2 BUT BY TIME WE
GET INTO YEAR THREE THAT WILL BE
ABLE TO TELL US WHERE WE WILL BE
AT THE END OF YEAR FIVE. WHEN WE
ARE READY GOING FOR RENEWAL WE
KNOW WHAT WILL BE IN THE
DATABASE AT YEAR TEN. WE KNOW
WHAT IS GOING TO BE THERE. ONE
OF THE IMPORTANT REASONS IS PI.
I GET ASKED WHEN THE METHYL
AVAILABLE. I SEE FOUR IN THE
DATABASE BUT NOT ANCESTRY. THIS
ALLOWS US -- WILL, NOT YET,
ALLOW US TO HAVE A SYSTEM SO
THAT NOT ONLY LONG-TERM VISION
IS YOU CAN LAUGHING IN. WHAT IS
AVAILABLE, DATABASE OF DATA. HOW
MANY LIMITS, BUT WHEN IN THE
DATABASE? NEXT SLIDE, PLEASE.
THIS IS SOMETHING I GET WEEKLY.
IT GOES TO THE LEADERSHIP. WHAT
YOU WILL SEE IS THERE IS A
TRACKING SYSTEM. BUT IN THE
EMAIL THERE IS KUDOS. HERE IS
HOW MANY WE HAVE SEEN SO FOR
THIS ONE IS HOW MANY A WEEK WE
NEED TO SEE. WENT UP FROM 26.4
AND DOWN TO 25.8. WITH KNOW
TRACKING HOW MANY WE NEED TO
SEE. THE TEAM GETS TO SEE THE
NUMBERS GO DOWN AND OTHERS GO
UP. THEY OWN THAT. THEY SEE HOW
MANY SCANS WE HAVE DONE, NO-SHOW
RATES AND HOW MANY DATABASES WE
HAVE PROVIDED. THE TEAM LOVES
THAT. THEY LOVE TO HEAR DR.
MEEKER GOT A KO1 LEAVE RAMMING
THE DATA. WE SEND OUT SO
SUCCESSES FOR THE TEAM. IT TAKES
A VILLAGE TO DO THAT SORT OF
THING. NEXT SLIDE. THIS IS SOME
OF THE GRANULARITY. THIS IS A
SYSTEM I'M WORKING WITH OTHERS.
IF YOU LOOK AT BOTTOM, THIS IS
DONE WEEKLY SO I SCROLL DOWN AND
SEE IT COUPLE YEARS. HOW MANY
ARE SEEING PROGRESS TOWARD
MILESTONE. THEN I CAN GO TO
IMAGING CENTER, SCHEDULING,
OUTREACH, DATA PORTAL, I KNOW
HOW MANY REQUESTS, HOW MANY AND
THIS INFORMS THE MEETINGS. IT IS
RECIPROCAL COMMUNICATION THAT ED
A LOUS US TO ADAPT AND FLEX TO
MEET GOALS AHEAD OF SCHEDULE.
INSTEAD OF PUSHING THE TEAM WE
CAN SLOW DOWN AND ALLOW PEOPLE
TO DO PHONE CALLS AND GET CAUGHT
UP. WE ALWAYS LIKE TO TRY TO
SLOW DOWN OVER SUMMERS, WHICH IS
DIFFICULT. WHICH IS WHEN
DEADLINES ARE. WE WANT PEOPLE TO
TAKE VACATIONS. THIS IS WHERE
WHAT I WAS GETTING AT IS WE KNOW
THE INFORMATION AND FALLING
BEHIND. THIS IS WHEN WE DECIDE
WHEN AND WHERE DO WE HERE
PEOPLE? A NEW RA FOR SCHEDULING
OR HERE? ONE OF THE THINGS
THAT'S COME OUT IS INSTEAD OF
HIRING A NEW RA FOR THE NEXT 12
MONTHS WE WILL LOOK AT THE SHOW
UP RATE AND NO-SHOW. THIS IS
GETTING PEOPLE BACK, REMINDER,
INTERVIEWING PEOPLE ONCE THEY
LEAVE. WHAT ARE THINGS WE CAN DO
TO HELP INCREASE CONNECTION TO
THE STUDY? THEN WITH ALL THIS
COMPONENT IT ALLOWS US TO BE
ABLE TO KNOW WHERE WE ARE AT AT
ANY GIVEN TIME SO THIS ALSO
ALLOWS US TO BETTER COLLABORATE
WITH INVESTIGATORS. SO WITH YCAP
FOR EXAMPLE WE KNEW WE WERE
GOING TO SHARE GWAS. BUT WE NEED
TO BE ABLE TO -- AT THIS POINT
WE WILL HAVE IT AND READY TO GO,
PULLED IT TOGETHER AND NOW THE
VIEW. NEXT SLIDE, PLEASE. ONE OF
THE THINGS I THINK IS IMPORTANT.
WE DIDN'T SAY WHY WE SAID THIS
IS WHERE WE WANT TO BUILD WITH
IT. NOT PARTICIPATING WAS A HUGE
OPPORTUNITY INSTEAD OF
HINDRANCE. WHAT WE DID IS BUILD
IT. ONE OF THE THINGS I'M SUPER
PROUD IS OVER THE LAST COUPLE
DECADES OUR TEAM SINGLE SITE HAS
RECRUITED CLOSE TO 12,000 ALL
FROM DIVERSE COMMUNITIES. RURAL,
IMPOVERISHED, AFRICAN-AMERICAN,
HISPANIC. IF YOU LOOK MOST OF
OUR SENIOR LEADERSHIP HAVE BEEN
WITH US A DECADE OR LONGER. SO
IT'S G
WHEN THEY JOIN THEY DON'T OFTEN
LEAVE. OUR SYSTEM IS CUSTOM. WE
BUILT IT SO PEOPLE CAN GET THE
DATA. THAT'S BEEN THE GOAL. TO
GET IT TO LONA. ARTHUR IS AN
MPI. THEY HAVE SCANS. IN THE
PROCESS NOW AND EXPECT IN JUNE
THE DATABASE TO BE THERE. WE ARE
DUMPING GENOMICS IN NOW. WE HAVE
BEEN ABLE TO SUPPORT OVER 350
DATABASES IN DIFFERENT COUNTRIES
IN THE LAST 18 MONTHS. I THINK
WE HAVE SUPPORTED FIVE TRAINING
GRANTS AND TEN ARE EQUIVALENT IN
THE LAST 36 SO LOTS OF THER
ANCILLARY THINGS. PEOPLE ARE
LEVERAGING DIANE TO COLLABORATE.
ABCDS CROSS COLLABORATES SO THE
DATA IS BEING LEVERAGED
SUBSTANTIALLY. NEXT SLIDE,
PLEASE. THERE'S A BUNCH OF
SLIDES. WANTED TO HIGHLIGHTS
JUNIOR INVESTIGATORS BECAUSE WE
ARE TRAINING A LOT OF
SCIENTISTS. THE DECK YOU WILL
HAVE ACCESS TO HAS THAT
INFORMATION BUT DIDN'T WANT TO
GO OVER TIME. SO I'M GO TO PAUSE
FOR QUESTIONS OR COMMENTS. THANK
YOU FOR YOUR TIME.
>> THANK YOU DR. RYAN. GREAT
TALK. LINDA, WANT TO START US
OFF?
>> THAT WAS FANTASTIC, GREAT.
I MIGHT HAVE MISSED IT BUT DO
YOU HAVE PLANS TO HAVE ANY OF
YOUR PARTICIPANTS TO COME BACK
FOR LONGITUDINAL INFORMATION ON
THINGS YOU MEASURE?
>> YEAH, I DIDN'T SAY THAT.
THANKS FOR THAT. SO YES,
EVERYONE COMES BACK EVERY 24
MONTHS. WE ACTUALLY HAVE OVER
1500 LONGITUDINAL ALREADY AND
PUSHING ALMOST A THOUSAND
LONGITUDINAL AMYLOID SCANS. IT
IS A LONGITUDINAL STUDY. SORRY
ABOUT THAT, LINDA.
>> THANKS FOR THE
PRESENTATION. A BIG QUESTION.
THE SUCCESS YOU HAVE HAD IS
EXPLAINED AND LOTS OF WAYS YOU
PRESENTED BY ORGANIZATIONAL
STRATEGIES. IN PARTICULAR YOUR
ABILITY TO RECRUIT DIVERSE
POPULATION, THE ONLY SPECIFIC
REFERENCE YOU MADE WAS YOUR
PHYSICAL LOCATION. YOU HAPPEN TO
BE IN AN AREA THAT IS DIVERSE.
DO YOU WANT TO COMMENT ON THAT
AND WHETHER THERE ARE OTHER
STRAT DPIS THAT MAKE YOU
RELATIVELY UNIQUELY SUCCESSFUL,
INCREDIBLE DIVERSITY IN
RECRUITMENT?
>> YEAH, I ALWAYS BALANCE
WITH HOW MUCH. I COULD SPEND
DAYS TALKING ABOUT JUST THAT
COMPONENT. SO WE HAVE BUILT A
VERY STRONG TIE WITH THE LOCAL
COMMUNITY. WE ARE IN THE
COMMUNITY, OVER 200 EVENTS A
YEAR. I PERSONALLY SPEAK TO THE
COMMUNITY ON A REGULAR BASIS,
MEET COMMUNITY LEADERS ARE PART
F OUR STUDY AND VIOLATE
CONFIDENTIALITY CONSTANTLY EVEN
ON MEDIA, HEY I'M PART OF THE
STUDY. WE HAVE SPENT OVER A
DECADE BUILDING THESE COMMUNITY
TIES. WE HAVE A UNIQUE APPROACH
IN THAT WE DO A STRONG
GRASSROOTS APPROACH. SO WE HAVE
ALSO THE COMMUNITY -- LARGE
COMMUNITY ENGAGEMENT SO AN
ENTIRE MEDIA TEAM. WE DO SOCIAL
MEDIA OUTP REACH. WE DO
TELEVISION, RADIO .
THE LARGEST BLACK-OWNED
SYNDICATED RADIO STATION IN THE
UNITED STATES IS IN DALLAS. THEY
WERE SO EXCITED THAT THEY AIRED
OUR RECRUITMENT FOR THE BLACK
PARTICIPANTS FOR FREE. THEY
BUILT IT. PUT IT TOGETHER. THEY
WERE SO EXCITED. THERE'S THE FOR
EXAMPLE THE STATE FAIR HAS A
LARGE FOOTBALL GAME WITH HBUs.
WE ARE THERE AND ON THE JUMBO
TRON AS ESPN IS ON. EVERYONE IS
EXCITED. I'VE BE ON SIBL WILKES,
LATERIS, WITH HIM YESTERDAY SO
WE ENGAGE COMMUNITY LEADERS
THEMSELVES. THE LADY WHO OWNS
THE MEDIA GROUP WE ARE ENGAGED
WITH, SHE IS THE ONE MCDONALD'S
WENT TO WHEN THEY WANTED TO DO A
NATIONAL CAMPAIGN TO THE BLACK
COMMUNITY. SAME THING IN
HISPANIC COMMUNITY. HISPANIC
CHAMBER OF COMMERCE, ET CETERA.
SO, TO ME, THE COMMUNITY
COMPONENT IS NO MORE DIFFICULT
THAN BUILDING THE CLINIC. IT IS
VERY DFRPT, TAKES A LOT OF TIME
YOU CANNOT HELICOPTER RESEARCH.
YOU HAVE TO BUILD IT. ONE OF THE
THINGS PEOPLE DON'T REALIZE IS,
YOU NEVER GO IN ASKING FOR
SOMETHING. YOU GO TO THE
COMMUNITY WITH, ALL RIGHT. WHAT
WOULD YOU LIKE? HERE IS WHAT WE
ARE INTERESTED IN AND NEED TO
UNDERSTAND AGING. WHAT DO YOU
NEED? WE GIVE TALKS ON DIABETES,
HYPERTENSION. IF THE COMMUNITY
SAYS WE NEED TO TALK ON SMOKINGS
A -- SMOKING ADOLESCENTS. IT IS
BUILDING A RELATIONSHIP. I WOULD
RATHER GO TO THE COMMUNITY. IT
IS MY PEOPLE AND I LOVE VERY
MUCH. WE HAVE VERY STRONGLY
CONN
CONNECTED. HOW DO YOU TAKE THE
TIME TO STRAT GUISTRAT GUISE AN
IMPLEMENT.
>> DAVID, FRANK?
>> I LOVE THE WORK AND THE
ORGANIZATION AND STRUCTURE. ARE
YOU COLLECTING BROAD
BIOMARK ERS, UNLESS I MISSED IT?
>> ABSOLUTELY, FULL SCALE
OMIX. METHYL, PROTEOMICS, MET
TAB LCHL, ALL.
>> I'M TALKING AMYLOID AND
TOW SETS.
>> WE HAVE BLOOD AMYLOID,
TOW, SAMOA. WE HAVE OTHER
GROUPS, 181, 217, GFAT. EMERGING
MARK ERS WE ARE LOOKING. IF WE
DON'T HAVE THEM WE ARE ADDING
THEM. ALL THOSE ARE THERE. IF
THEY ARE NOT THEY WILL BE THERE.
TERRIFIC, THANK YOU.
>> THANK YOU. I KNOW WE HAVE
LIMITED TIME BUT BRIEFLY CAN
SOMEBODY BE ON A THER PETE IK
AND STILL BE IN THE TRIAL? I
THINK THIS IS M DOING UP MORE
AND MORE IN LONGITUDINAL
STUDIES.
>> SO SOMEONE IS PRESCRIBED
AN AMYLOID DRUG -- WE DON'T
REMOVE PEOPLE. YOU ARE IN UNTIL
YOU SAY YOU ARE NOT IN. WE DON'T
EXCLUDE, UNLESS WE MUST. IF
SOMEONE GOES INTO A TRIAL
NORMALLY TRIALS EXCLUDE THEM BUT
WE DON'T REMOVE THEM. WE WILL
SIMPLY PROVIDE A GAP AND SAY AS
LONG AS YOU ARE IN THE TRIAL,
WHEN YOU ARE DONE, COME BACK.
THEY ARE WITH US. WE ARE
MONITORING THAT. WE HAVEN'T HAD
ONE YET GO ON ONE OF THE DRUGS.
THAT IS NOT SURPRISING
GHOOIVGHOOIV GIVEN
THE COMMUNITIES AND ACCESS. WE
WILL MONITOR IT.
>> AN ARTICLE I WAS READING
THIS, YOU ARE SO CENTRALIZED,
YOU AND YOUR TEAM ADDRESSED THIS
COMPLICATED AREA. I WAS READING
ABOUT THE POINT OF VIEW THAT
SOCIOECONOMIC -- THIS IS FOR
LATE-ONSET ALZHEIMER'S, RISK OR
PROGRESSION. SOCIOECONOMIC
FACTORS ARE MORE POWERFUL THAN
ANY GENETIC FACTOR. YOU ARE
COLLECTING BOTH SO --
>> I CAN TELL YOU THAT WE
HAVE DATA NOW SUGGESTING LIKE
SOME PRIOR DATA HAS TALKED ABOUT
CERTAIN SOCIOECONOMIC FACTORS
ARE NOT RELATED TO AMYLOID OR
WHATEVER. WHAT WE THINK IS
THERE'S BEEN RESTRICTED RANGE IN
SOCIOECONOMIC REPRESENTATION IN
STUDIES. WE ABSOLUTELY SEE
SOCIOECONOMIC FACTORS BROADLY
DEFINED. SO WHERE YOU LIVE, ET
CETERA. VERY STRONGLY LAIN
LINKED, INCLUDING AMYLOID, TOW,
NEUROGENERATION, WHICH IS WHAT I
WAS GETTING AT EARLIER. I DON'T
THINK WE CAN UNDERSTAND THE
BRIAN BIOLOGY OF AGING IN
ABSENCE OF SOCIAL YOU CULTURAL
FRAME. DATA IS BEARING MORE AND
MORE OUT. EVEN PEOPLE LOOKING,
THERE IS ABSTRACT GOING OUT.
PERCEIVED RACISM AS A VERY
STRONG FACTOR ASSOCIATED WITH
EVEN IM IMAGING AMONG HISPANIC
AND NON-AMERICANS BUT NOT
NON-HISPANIC WHITES. DIABETES
RELATED TO TOW AMONG HISPANICS.
IT IS COMPLICATED BUT THAT IS
ENCOURAGING THAT. IS HOW WE GET
TO PRECISION MANAGED APPROACHES.
WITHOUT STUDYING SOCIAL OWE
CULTURAL DETERMINANTS IT IS LIKE
STICKING OUR HEAD IN THE DIRT.
>> I LOVE THAT. WHAT YOU ARE
DOING SO SO IMPORTANT. IT IS SO
EASY TO STAY IN A COMFORT ZONE
OF GENETIC AND BIOLOGIC BUT FACT
SOCIOECONOMIC STATUS CAN TRUMP
THAT IS SO IMPORTANT SO THANK
YOU FOR DOING THAT.
>> THANKS, FRANK.
>> ALL RIGHT. THANK YOU AGAIN
DR. RYAN. REALLY FANTASTIC TALK.
THANKS FOR YIELDING ALL OUR
QUESTIONS TOO. I APPRECIATE.
THERE IS A FEW COMMENTS AND
KUDOS IN THE CHAT ALSO. ALL
RIGHT. MOVING ON WE ARE NEXT
STOP WE ARE GOING TO BE HEAR ING
FROM OUR INTRAMURAL PROGRAM SO I
WILL TURN THIS OVER TO DIRECTOR
OF NIA'S INTRAMURAL PROGRAM DR.
FRUGI.
>> INTERESTING DAY. I WILL
SAY I WAS GLAD TO BE HERE AND
LISTENING. WE WILL START TALKING
ABOUT THE INTRA MURAL PROGRAM
AND INVITING THE SPEAKER MARK
COOKSON, RECENTLY NOMINATED
CHIEF OF NEUROGENETIC AND EXPERT
IN BIOLOGY AND ITS IMPORT IN
PARKINSON'S AND ALSO HAVE BEEN
INVOLVED IN LARGE PROJECT , THE
WAY THEY GENERATE THE CELLS SO
CAN BECOME AVAILABLE TO
COMMUNITY AND SEE MUTATION. I
LIKE TO INVITE MARK TO OPEN WITH
THIS PRESENTATION. WE MAY BE IN
THE CLOSED SESSION. THE PROGRAM
AND I WILL ADDRESS QUESTIONS IF
YOU HAVE ANY QUESTIONS. MARK.
>> YEAH GREAT, THANK YOU,
LUIGI. GREAT TO MEET EVERYONE
TODAY. WONDERFUL CHANCE TO
SPEAK. IF I COULD HAVE THE
SLIDES UP. JASMINE SHOULD BE
SHOWING THEM. AWESOME, THANKS.
SO WHAT PROMPTED THIS
PRESENTATION TODAY WAS THE FACT
THAT MANY OF YOU KNOW OUR
INTRAMURAL LABS ARE REVIEWED
EVERY FOUR YEARS. OURS WAS A
COUPLE YEAR AGO SO WHAT I HAVE
SCHEMATIC HIGH-LEVEL OVER VIEW.
THEN I WILL TRANSITION TO THINGS
THAT ARE NEWER WE HAVE MOSTED
THE LAST COUPLE YEARS. BUILDING
OFF THE LAST TALK, INCREDIBLY
IMPRESSED ABOUT MULL FACTORIAL
NATURE OF THE DISORDERS, I WILL
FOCUS ON GENETICS AND REASON
THAT IS RELEVANT TO YOU. THE
REASON WE ARE PART OF INTRAMURAL
IS HIGHLIGHTED BY THIS. THIS IS
FROM PARKINSON'S DISEASE. THIS
IS A MACHINE LEARNING APPROACH
LOOKING AT VARIOUS FACTORS THAT
CAN BE MEASURED AND CLASSIFIED.
IF YOU LOOK AT THINGS THAT
DETERMINE RISK, NON-GENETIC,
NON-AGING FACTORS ARE
SIGNIFICANT IMPORTANT HOWEVER SO
ARE GENETIC FACTORS, RIGHT. SO
YOU CAN COME UP WITH VARIOUS
ITERATIONS OF THIS BUT YOU END
UP WITH THE SAME THING. GENETIC
RISKS, NON-GENETIC RISKS
INCLUDING SOCIAL CONSTRUCTS ON
AGING AND ALL INTERACT TO GIVE
RISK OF DISEASE. WE HAVE
APPROACHED GENETIC NOT BECAUSE
IT IS MORE IMPORTANT BUT MORE
SCALEABLE AND REPRODUCIBLE
SCIENCE. THE NEXT SLIDE. SO
AGAIN, FIRST PART IS REALLY
ABOUT THE WORK WE HAVE DONE. SO
WHEN WE TALK ABOUT LAPSE IN THE
INTRAMURAL PROGRAM MANY ARE
MULTI -PI LABS. EACH RUNS
RELATIVELY SMALL TEAM. THIS IS
OUR CURRENT COHORT .
THE THING I WANT EVERYONE TO
UNDERSTAND IS FIRST OF ALL
WITHIN THIS THERE ARE IMPORTANT
DISTINCTIONS FROM WHAT PEOPLE
DO. CLINICAL RESEARCH, HUMAN
GENETICS AND POPULATION SCALE
AND MOUSE. LUIGI HIGHLIGHTED
ALREADY, THAT IS ACTUALLY MY
AREA OF INTEREST. NEXT SLIDE. I
THINK IT IS IMPORTANT SO WE HAVE
BEEN IN EXISTENCE FOR 22 YEARS.
SO NOT QUITE HALF THE TIME NIA
HAS BEEN HERE. BUT WE HAVE MADE
BIG IMPACT IN NEURODEGENERATIVE
DISEASES WE STUDY. I WOULD SAY
ABOUT HALF THE LAB IS FOCUSED ON
GENETICS. THAT STARTS MONOGENIC
AND MOVED TO GENO WIDE STUDIES.
WE HAVE BEEN RESPONSIBLE FOR
DISCOVERY OF MAJOR IN
PARKINSON'S AND THE FTD SPECTRUM
SO LOOK TO 72 AS WELL AS RARE
ALILS IN ALZHEIMER'S. THE TWO
PAPERS IS ESTABLISH ALREADYING
-- ESTABLISHING A RISK FACTOR. I
COME BACK TO SOME OF THIS LATER.
THIS OTHER HALF WORKS ON MODELS.
SOME OF THE WORK HAS BEEN -- WE
HAVEN'T TAKEN CLINICAL TRIALS
BUT HAS BEEN INFORMATIVE. SOME
OF THE IDEAS THAT COME ARE IN
PARKINSONS, WHICH IS GREAT.
ANOTHER THING IS NOT WE ARE SO
HAPPY WITH WHAT WE FOUND BUT
STILL PUSHING TO MOVE FORWARD. I
WANT TO EMPHASIZE THEY ARE
DISTINCT THE INTERACTIONS ARE
IMPORTANT. NEXT SLIDE. JUST
AGAIN SORT OF VERY BIG OVERVIEW.
THESE THEME SLIDES WERE DONE BY
MATSON, TOOK OUR PAPERS AND
CLASSIFIED THEM. YOU CAN SEE IN
THE GREENISH COLOR. THIS IS
BASED ON CITATIONS. OTHER
FACTORS OF DEMENTIA AND
SOMEWHERE IN HERE DEMENTIA AND
ALS. THOSE ARE MAJOR AREAS.
SPECIFIC GENES THAT COME ON ARE
IN THAT CLOUD. ON THE RIGHT HAND
HERE AND THERE SORT OF PINK
COLOR ARE THE MATHEMATICAL
APPROACHES. WE USE A LOT OF GENE
IDENTIFICATION STRATEGIES AND
GENE STUDY, WHICH I WILL TALK
ABOUT. PARTICULARLY I THINK IN
THE LAST TEN YEARS WE HAVE MOVED
AWAY FROM MALL APPROACHES, WHICH
ARE POWERFUL. AGAIN THIS IS
SOMETHING WE HAVE DISCUSSED IN
THIS MEETING, HOW USEFUL TO
IMPROVE COHORT SCIENCE. NEXT
SLIDE. I THINK LIKE EVERYONE ON
THIS CALL TODAY, NONE OF THIS
SITS IN A VACUUM. THIS IS JUST
SMATTERING OF HIGH-IMPACT
PAPERS. VIRTUALLY ALL ARE A
CONSORTIUM PAPER OR
COLLABORATIVE WITH OTHER
CENTERS. THAT IS DRIVEN THAT THE
STUDIES ARE DRIVEN BY SO MANY
PARTICIPANTS IT IS ALMOST
IMPOSSIBLE FROM A SINGLE CENTER.
WE HAVE DONE IT IN CONTEXT OF A
COLLABORATIVE EFFORTS. NEXT
SLIDE. SO HERE IS A VI
VISUALIZATION. WE HAVE STRONG
LINKS THE SORT OF THREE, FOUR
BIG CENTERS, BUT IN ESSENCE ALL
SORT OF GO ACROSS THE GLOBE.
COME TO THAT IN THE SECOND HALF.
REALLY ABOUT OUR OWN
SELF-DIRECTED EFFORTS TO GET
OUTSIDE OF OUR WELL ESTABLISHED
COLLABORATIVE NETWORK. NEXT
SLIDE. I'M VERY PROUD TO SAY, I
KNOW LUIGI HAS SAME STANDARDS
FOR THE INTRAMURAL PROGRAM WE
HAVE MAINTAINED PRODUCTIVITY
OVER THAT 22 YEARS. I DON'T KNOW
HOW CRITICAL THE NUMBERS ARE. I
THINK MANY LARGE CENTERS WOULD
HAVE SIMILAR MEASURES. THE ONE
THING I WANT TO HIGHLIGHT IS
WHERE WE PUBLISH. CLINICAL AND
NEUROLOGY ARE THE SUBJECTS WE
HAVE HIT THE MOST BUT ALSO THERE
ARE PUBLICATIONS ARE HIGHLY
RESPECTED AND CITED. ABOUT 20%
OF OUR MAYBE FROM LITTLE BIT
MORE OF OUR PUBLICATIONS ARE IN
TOP TEN CITATIONS, WHICH IS NOT
EGOTISTICAL BUT SHOWING WE HAVE
HAD AN IMPACT AND IDEAS WE HAVE
BUILT ON. NEXT SLIDE. THEN, YOU
KNOW, A LOT OF WHAT I'M TALKING
ABOUT IS PI DRIVEN BUT A LOT OF
WORK IS DONE BY TRAINEES WE GET
IN THE INTRAMURAL PROGRAM AND WE
ARE PROUD OF TRAINEES AND THEY
DO VERY WELL. THAT WAS A VERY
BRIEF SUMMARY AT THE LAB.
LEANING ON OUR PRIOR HISTORY AND
PRODUCTIVITY. WHAT I PRESENTED
WAS FUTURE DIRECTIONS. THIS IS
LITERALLY THE SLIDE I PUT UP. AT
THE TIME THERE WERE FOUR AREAS
WE FELT WERE IMPORTANT. ONE WAS
-- AGAIN, THIS HAS COME UP
SEVERAL TIMES TODAY. I THINK WE
ALL RECOGNIZE THE ASPECT OF
SCIENCE HAS BEEN FOCUSED ON
EUROPE PANDEMIC NORTH AMERICA
ANCESTRY POPULATIONS. SO WE
REALLY WANTED TO PUT LOT OF
EFFORT INTO GOING OUTSIDE THAT.
I WILL TALK ABOUT THAT IN THE
NEXT FEW SLIDES. WE ALSO
RECOGNIZE THOUGH WE HAVE DONE
WELL WITH ONE-TO-ONE GENETIC
RELATIONSHIPS, SINGLE GENE OR
COMPLEX GENETICS INTO SINGLE
FI
PHENOTYPES, THE UNDERLIE ING IS
MORE COMPLEX. WE ARE LOOKING AT
CROSSDISORDERS. LUIGI MENTIONED
MOVE INTO CELLULAR MODELS. I
WILL SHOW YOU THAT IN A SECOND.
I THINK THEY FOUND DEVELOPMENT
OF ISPC MODELS BUT PARTICULARLY
IN CONJUNCTION WITH CRISPR KAS 1
EDITING HAS MAKE EN SOMETHING
THAT WAS BE SPOKE TO SOMETHING
SCALEABLE. I SPOCK TO MOVE THE
SCALE OF SCALABILITY. AT THE
SAME TIME THE LAB USES INDIVA.
WE HEARD THIS FROM THE TALK ON
DOWN'S SYNDROME. MOUSE MODEL S
HAVE PRO 'S AND CONS. ONE OF THE
THINGS THAT'S BECOME FEASIBLE IS
FOCUS ON ANDROGE --AND
ANDOGENOUS MODELS. I WILL END
WITH A LITTLE TRANSLATIONAL
EFFORTS. WE ARE NOT A FULL LAB
BUT AIM TO HAVE TRANSLATIONAL SO
I WILL SHOW YOU A COUPLE
EXAMPLES. NEXT SLIDE. IT IS A
TRUISM IN HUE MAP GENETIC
STUDIES LIKE MOST ASPECTS OF
SCIENCE WE HAVEN'T DONE WELL IN
REPRESENTATION. THIS WAS
PUBLISHED LAST YEAR. THE FIRST
GENE STUDY IN PEOPLE FROM AFRICA
IN CONTEXT OF PARKINSON'S. A
RELATIVELY LARK STUDY. VE
CONTROLLED BUT LARGELY FROM WEST
AFRICA, NIGERIA IN PARTICULAR.
RECENT AFRICAN ANCESTRY WITHIN
THE U.S. THAT LED, THOUGH THE
NUMBER OF CASES SMALL TO SINGLE
GENOME LOCKER OF GBA1. MANY OF
YOU WILL KNOW THAT'S BEEN
PREVIOUSLY ASSOCIATED AS RISK
FACTOR IN EUROPEAN POLL
ALLEGATIONS BUT THIS IS THE
FIRST BONA FIDE RISK FACTOR IN
WEST AFRICA AND RECENT
POPULATIONS. WAS INTERLY
INTERESTING IS OTHER POPULATIONS
IT IS NOT O HOMEZYGOUS FOR
DOSHAYS DISEASE. IT IS A NOVEL
MECHANISM. NONE OF THIS HAPPENS
BY GOING IN AND TAKING THINGS
BUT BY BUILDING UP CAPACITY.
ACTUALLY THE SENIOR FROM THIS
PAPER IS NOT OUR LAB BUT FROM
NIGERIA. THIS IS VERY MUCH
PROJECTS AIMED AT PEOPLE
MAINTAINING DATA SOVEREIGNTY,
BEING SUPPORTED IN GLOBAL EF
EFFORTS. MORE RECENTLY THERE WAS
A POWER BOOST THAT ALLOWED US TO
FIND 12 NOVEL THAT WOULD HAVE
ONLY BEEN SEEN IN EUROPEAN OR
EUROPEAN-AMERICAN ANCESTRY. FOR
US THIS IS BOTH MATTER OF
JUSTICE AND GLOBAL JUSTICE AND
SCIENTIFICALLY INFORMATIVE. WE
WERE ABLE TO FIND MAPS FROM
PRIOR POPULATIONS. INCREDIBLY
INFORMATIVE WORK. NEXT SLIDE. I
MENTIONED THIS. A LOT OF WORK IS
APPROPRIATELY FOCUSED ON GENETIC
RISK AND DISORDERS. THE
PATHOLOGY THAT SHOW UP IN LATER
AGE S IS MORE COMPLEX. THIS IS
AN ISSUES STUDY OF EPIGENICS
LOOKING AT LOTY DEMENTIA, WHERE
THE PHENOTYPE IS THE DISORDER
BUT PATHOLOGY BUT LUIBITES. IF
YOU LOOK AT THIS SORT OF
RELATIVELY SMALL, WHAT YOU SEE
IS MIXTURE OF WHAT WE PREVIOUSLY
CALLED PARKINSONS OR ALILS AND
ALZHEIMER'S AND DEMENTIA. IN
FACT, AT LEAST THIS LEVEL IS
PRETTY EVEN MIX OF BOTH.
DOMINATING THE GENOMIC
LANDSCAPE. THAT REALLY TELLS YOU
IN A WAY THAT SUPPORTS THIS,
MANY OF THESE HAVE COMPLEX
GENETIC AND OVER LAPS. NEXT
SLIDE. THAT IS PROBABLY
UNDERESTIMATE. WHAT WE HAVE
LOOKED AT ARE VARIANTS, ALILS,
THE SO-CALLED SNIPS. WE KNOW
THERE IS A LOT OF SO-CALLED
HIDDEN VARIATION AROUND
STRUCTURAL VARIATION SO
INSERTIONS, DELL ELECTROCU -- D
AND VARIOUS THINGS. OTHERS
LOOKED FOR OTHER VARIOUS BODIES
AND FOUND NOVEL AROUND TCPM1
VALIDATING THE COHORTS FOR THE
LUDY BODY DEMENTIA. MY FEELING
IS WE WILL SEE INCREASING NUMBER
OF THESE TYPES FACILITATED BY
LONG RANGE SEQUENCING, SOMETHING
UP AND RUNNING IN THE LAB. AS
MANY OF YOU KNOW PRIOR STUDIES
USING GENOME STUDIES HAVE
FOCUSED ON ACCESSIBLE AND OTHER
INFORMATION. ONTO MORE OF THE
FUNCTIONAL WORK, AS LUIGI SAID,
THIS IS WHAT I'M INTERESTED IN.
THE CHALLENGE HAS BEEN TO TAKE
THAT RICH INFORMATION FROM
GENETICS AND TRANSLATE IT. AS I
MENTIONED THE DEVELOPMENT OF
ROBUST ATTITUDE IS MADE THAT
VERY SCALEABLE. THIS IS A
PROJECT I CO -LEAD AND
INVESTIGATOR AT NDS. I WILL
EMPHASIZE THE COLLABORATIVE
NATURE OF THE LAB. WHERE WE
DEVELOP WHAT WE CALL THE IPSC
INITIA
INITIATIVE. IF ALILLS ARE
ASSOCIATED WITH MULTIPLE
DISEASE, I WILL COME BACK, IF
THEY CAN SHOW MULTIPLE
PHENOTYPES WE SHOULD LOOK ACROSS
CONSISTENT BACKGROUNDS. SO THIS
IS AS MUCH ENGINEERING AS
SCIENCE PROJECT. I'M PLEASED TO
SAY WE HAVE SUPPORT FROM CARD
AND FROM TRANS BERGEN AND
PARKINSON'S FOCUSED GROUP TO
EXPAND THAT SIDE OF OF ADRD.
WHERE THIS IS, IF YOU WISH YOU
CAN GO TO JACK'S WOOILT WEBSITE,
WHERE YOU ORDER MICE AND ORDER
THIS SERIES NOT ONLY ALILS OF
INTEREST SO YOU KNOW WHAT YOU
A
ARE GETTING. WE HAVE SHIFTED TO
3200 LINES. IN PARALLEL THE MIX
IS STILL IN DEVELOPMENT WITH
THIS SO I APPRECIATE THE
AVAILABILITY. THOSE DATA SETS
WILL BE GENERATED AND AVAILABLE.
SOMETHING I LIST, THE FIRST TIME
THIS HAS BEEN ANNOUNCED, THEY
WERE ACTUALLY SETTING UP FOR
JUNIOR EARLY CAREER RESEARCHERS
IN WORKSHOPS TO RELAY A LOT OF
THIS INFORMATION ABOUT HOW YOU
EPG NEAR AND MANIPULATE IPSC.
NEXT MAY THESE WILL BE SHARED.
SYMPOSIUM AND IN-PERSON WORKSHOP
WORKING WITH JACKSON LAB. IF YOU
ARE TRAINEES LET ME KNOW. WE
HAVE A FEW SPOTS FILLING UP
FAST. JUST AN EXAMPLE BEYOND
WHAT WE DO AND MORE INTO
ENGAGEMENT IN THE PROPER
COMMUNITY. NEXT SLIDE. THE LAST
SORT OF IN THE CELL MODELLING IS
OF COURSE WHAT I TALKED ABOUT SO
FAR FROM VARIANTS, WHICH WE
EXPECT TO HAVE HIGHER EFFECTS IN
CELLS BECAUSE SHOULD HAVE
STROPSTR
STRONGER APPROXIMATE. ONE OF THE
CHALLENGES IS CODING VARIANTS OF
HIGH VALUE TO NON-CODING
VARIANTS. SO JUST VERY BRIEFLY
AS PUBLICATION FROM TWO YEARS
AGO TRANSLATION MATSON WHERE WE
DID THIS LOOKING ABOVE HUMAN
BRAIN AND IPSCs. IN THIS CASE
THE INFLAMMATORY CELLS OF THE
BRAIN. REALLY KEY TO THIS WAS
HOW POPULATION LEVEL IPSCs WHERE
WE HAVE THE SAME VARIANTS AND WE
COULD CITE -- REALLY DRIVE THE
STUDY BY LOOKING AT VARIANTS
ASSOCIATED WITH DISEASE BOTH IN
HUMANS AND IPSCs. THE MESSAGE IS
WE FEEL THIS IS PREDOMINANTLY
WORKING THROUGH A MICRO ALIL
STATE. AT THE SAME TIME IPSCs
ARE GOOD. GOOD FOR LOOKING AT
ANDOGENOUS GENETICS BUT IN TACK
SYSTEMS WITH COMPLEXITY CNS HAS.
MIGHT BE COMPLICATED TO LOOK AT
THINGS LIKE AGING. HERE IS AN
EXAMPLE. A SERIES OF SMALL
FAMILIES WITH RECESSIVE
INHERITANCE. WITH DEFECT IN
SYNTHESIS. WHAT BEN'S GROUP WERE
ABLE TO DO IS SHOW WHEN THEY
KNOCK DOWN THE SAME GENE IN A
SPECIFIC MANNER YOU COULD HAVE
PHYSIOLOGICAL EFFECTS IN MOTOR
LEARNING. THIS IS WE HAVE TAKEN
IT BACK TO THE HUMANS. SO AGAIN,
I WANT YOU TO SORT OF GET THE
SENSE HERE OF HOW TO BUILD TOOL
SETS ACROSS SPECIES TO LOOK AND
SEE WHERE ANDOGENOUS GENES HAVE
EFFECT IN CELLULAR CONTEXT. THIS
IS FROM BEN'S WORK AGAIN. THIS
IS A PROTEIN WIDELY STUDIED. HAS
AN INTERESTING ALIEL, WHERE SOME
INDIVIDUALS HAVE SHOCK MARI
TOOTH NEW NEWER P -- NEUROPATHY
HE WAS ABLE TO LOOK AT THE
EFFECTS OF THIS IN DOPAMINE
NEURONS AND SHOW THEY HAVE AL
STRESS. SO THE POINT, JUST
VIGNETTES, REALLY, IS HOR
IMPORTANT IT IS TO MOVE FROM
CONTEXT OF SINGLE GENES AND
ALIELS INTO PHYSIOLOGICAL
CONTEXT TO SEIZE OUT EFFECTS ON
DIFFERENT CELL TYPES. SO LAST
TWO THINGS, NOT A FULLY
TRANSITIONAL LAB. THIS WAS LED
BY -- WE MEET EARLIER, MANY OF
YOU WILL KNOW. LOOKING AT
SPECIFIC P38 HE'S SHOWN HAS
INFLAMMATION AND SHOW CAN
IMPROVE IN IPSC. SOME MODELS,
MOUSE MODELS, MULTIPLE MEASURES
INCLUDING NEUROINFLAMMATORY
SIGNALLING. THIS IS ONE OF THOSE
CURRENTLY FORWARD TO CLINICAL
TRIALS. NEXT SLIDE. I THINK LIKE
A LOT, WE ARE ALWAYS KEEN TO GO
PATIENTS, BRIAN TO THE PHD,
DISCOVER OF 72, WHICH IS AN ALS
SPECTRUM GENE, BRIAN HAS A LONG
INTEREST IN NATURAL HISTORY.
RECENTLY JOINED IN ALL ACROSS
DIFFERENT DIFFERENT GENETIC TD.
TWO THINGS. FIRST OF ALL NATURAL
HISTORY AND BIOMARKER, CRITICAL.
MOVING FORWARD TO GENE OR TYPES
OF THERAPY. BRIAN HAS AN
INITIATIVE WITH NATIONAL CENTER
FOR ADVANCED TRANSLATIONAL
SCIENCES TO LOOK AT THE
NUCLEOTIDES, ESPECIALLY IN THE
CONTEXT OF THESE DISEASES.
REALLY AGAIN SORT OF BRINGING
THIS FROM GENETICS THROUGH THE
MODELLING, BACK TO THE PATIENTS.
AT LEAST WHERE THAT IS
APPROPRIATE. LAST SLIDE. WE ARE
BEEN AT IRP THE LAST 20 YEAR,
HAVE LOT OF PRODUCTIVITY.
CURRENT EFFORTS WERE EXPANDING
THAT OUT HOW WE LOOK IN THE
PAST. NOT ONLY PRODUCTIVE BUT
ALSO IMPORTANT. I THINK WE ARE
LEARNING A LOT FROM GENETICS AND
MOVING THAT TO MODELS. HOPEFULLY
BRING SOME BACK TO PATIENTS. SO
THANKS FOR YOUR TIME. REALLY
APPRECIATE THE OPPORTUNITY TO
SPEAK. HAPPY TO TAKE QUESTION ,
IF THERE ARE ANY, THANKS. THANK
YOU, OUTSTANDING.
>> THANK YOU FOR THE GREAT
OVERVIEW OF LABORATORY GENETICS.
QUESTIONS FROM OUR -- NOT
HEARING ANY. MARK, THANK YOU.
OPINION APPRECIATE YOUR
PRESENTATION. SO AT THIS POINT
IN THE -- OUR DAY TWO THIS WILL
BE THE CONCLUSION OF OUR 151ST
MEETING OF THE NATIONAL ADVISORY
COUNCIL ON AGING OF THIS OPEN
SESSION. SO AT THIS POINT WE
WILL BE CONCLUDING THE OPEN
SESSION. I ASK THAT ALL
COUNCILMEMBERS AND THE DIVISION
DIRECTORS FOR NIH PLEASE STAY
ON. WE WILL HAVE A SHORT CLOSED
SESSION WITH LUIGI. THEN WE WILL
CONCLUDE THE MEETING OVERALL. SO
THANK YOU AGAIN, EVERYONE. WE
WILL START AGAIN IN JUST A
MINUTE.
>> THANK YOU KEN. I WILL
SHARE MY SLIDES WITH YOU IN A
COUPLE MINUTES WHEN YOU TELL ME
TO DO IT.
>> OKAY, GREAT.
>> MAKING SURE THAT EVERYBODY
ELSE SIGNS OFF. EVEN JASMINE,
MYSELF AND TEL ZOOM PEOPLE WILL
BE GONE. KEN, YOU WILL BE THE
HOST. WHEN APPROPRIATE, END THE
MEETING AFTER THAT.
>> THANK YOU.